Neurotheranostics as personalized medicines

Nie, 2007, Nanotechnology applications in cancer, Annu. Rev. Biomed. Eng., 9, 257, 10.1146/annurev.bioeng.9.060906.152025 Xie, 2010, Nanoparticle-based theranostic agents, Adv. Drug Deliv. Rev., 62, 1064, 10.1016/j.addr.2010.07.009 Ross, 1998, The HER-2/neu Oncogene in Breast Cancer: Prognostic factor, Predictive factor, and Target for Therapy, Oncologist, 3, 237, 10.1634/theoncologist.3-4-237 Lukashov, 1998, HIV heterogeneity and disease progression in AIDS: a model of continuous virus adaptation, AIDS (London, England), 12, S43 Bouzid, 2012, Inflammatory bowel disease: susceptibility and disease heterogeneity revealed by human leukocyte antigen genotyping, Genetic testing and molecular biomarkers, 16, 482, 10.1089/gtmb.2011.0132 Kelkar, 2011, Theranostics: Combining Imaging and Therapy, Bioconjug. Chem., 22, 1879, 10.1021/bc200151q Blau, 2018, Image-guided surgery using near-infrared Turn-ON fluorescent nanoprobes for precise detection of tumor margins, Theranostics, 8, 3437, 10.7150/thno.23853 Janib, 2010, Imaging and drug delivery using theranostic nanoparticles, Adv. Drug Deliv. Rev., 62, 1052, 10.1016/j.addr.2010.08.004 Pene, 2009, Toward theragnostics, Crit. Care Med., 37, S50, 10.1097/CCM.0b013e3181921349 Ozdemir, 2006, Shifting emphasis from pharmacogenomics to theragnostics, Nat. Biotechnol., 24, 942, 10.1038/nbt0806-942 Chapman, 1983, History of the discovery and early use of radioactive iodine, JAMA, 250, 2042, 10.1001/jama.1983.03340150084036 Mumtaz, 2009, Radioiodine I-131 for the therapy of graves' disease, The Malaysian journal of medical sciences : MJMS, 16, 25 Silberstein, 2012, Radioiodine: the Classic Theranostic Agent, Semin. Nucl. Med., 42, 164, 10.1053/j.semnuclmed.2011.12.002 Pryma, 2014, Radioiodine Therapy for Thyroid Cancer in the Era of Risk Stratification and Alternative Targeted Therapies, J. Nucl. Med., 55, 1485, 10.2967/jnumed.113.131508 Shukla, 2017, Comprehensive Analysis of Cancer-Proteogenome to Identify Biomarkers for the early Diagnosis and Prognosis of Cancer, Proteomes, 5, 28, 10.3390/proteomes5040028 Shruthi, 2016, Selvamani, Proteomics: a new perspective for cancer, Advanced biomedical research, 5, 67, 10.4103/2277-9175.180636 Conn, 2008, Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation, J. Biol. Chem., 283, 26518, 10.1074/jbc.M803337200 Chapman, 2013, Nanoparticles for cancer imaging: the good, the bad, and the promise, Nano Today, 8, 454, 10.1016/j.nantod.2013.06.001 Chinen, 2015, Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence, Chem. Rev., 115, 10530, 10.1021/acs.chemrev.5b00321 Cormode, 2009, Nanotechnology in medical imaging: probe design and applications, Arterioscler. Thromb. Vasc. Biol., 29, 992, 10.1161/ATVBAHA.108.165506 Goel, 2017, Positron emission tomography and nanotechnology: a dynamic duo for cancer theranostics, Adv. Drug Deliv. Rev., 113, 157, 10.1016/j.addr.2016.08.001 Agdeppa, 2009, A review of imaging agent development, AAPS J., 11, 286, 10.1208/s12248-009-9104-5 Toy, 2014, Targeted nanotechnology for cancer imaging, Adv. Drug Deliv. Rev., 76, 79, 10.1016/j.addr.2014.08.002 Savla, 2017, Nanoparticle design considerations for molecular imaging of apoptosis: Diagnostic, prognostic, and therapeutic value, Adv. Drug Deliv. Rev., 113, 122, 10.1016/j.addr.2016.06.016 Sikkandhar, 2017 Yaari, 2016, Theranostic barcoded nanoparticles for personalized cancer medicine, Nat. Commun., 7, 13325, 10.1038/ncomms13325 E.S.O. Radiology, 2015, Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR), Insights into Imaging, 6, 141, 10.1007/s13244-015-0394-0 Personalized medicine, 2011, Identifying the appropriate patient through biomarkers in oncology, P & T, 36, 3 Portnow, 2013, The history of cerebral PET scanning, From physiology to cutting-edge technology, 80, 952 Truffi, 2018, Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells, Sci. Rep., 8, 6563, 10.1038/s41598-018-24968-x Henry, 2017, Human Epidermal Growth factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis, PET Clinics, 12, 269, 10.1016/j.cpet.2017.02.001 Massicano, 2018, Targeting HER2 in Nuclear Medicine for Imaging and Therapy, Mol. Imaging, 17, 10.1177/1536012117745386 Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann. Neurol., 55, 306, 10.1002/ana.20009 Lamberts, 1990, Somatostatin-Receptor Imaging in the Localization of Endocrine Tumors, N. Engl. J. Med., 323, 1246, 10.1056/NEJM199011013231805 Graham, 2011, Radiopeptide imaging and therapy in the United States, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 52, 56s, 10.2967/jnumed.110.085746 Krenning, 1993, Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients, Eur. J. Nucl. Med., 20, 716, 10.1007/BF00181765 Valkema, 2002, Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience, Semin. Nucl. Med., 32, 110, 10.1053/snuc/2002.31025 Albert, 1998, Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man, Bioorg. Med. Chem. Lett., 8, 1207, 10.1016/S0960-894X(98)00187-5 Hammond, 1993, Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue, Br. J. Cancer, 67, 1437, 10.1038/bjc.1993.266 Melis, 2005, Localisation and mechanism of renal retention of radiolabelled somatostatin analogues, Eur. J. Nucl. Med. Mol. Imaging, 32, 1136, 10.1007/s00259-005-1793-0 Jamar, 2003, 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion, Eur. J. Nucl. Med. Mol. Imaging, 30, 510, 10.1007/s00259-003-1117-1 Barone, 2005, Patient-specific Dosimetry in predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney volume and Dose Rate in Finding a Dose–effect Relationship, J. Nucl. Med., 46, 99S Delaloye, 1997, Highlights of the Annual Meeting of the European Association of Nuclear Medicine: Copenhagen 1996, Eur J Nuel Med, 24, 219, 10.1007/BF02439558 Strosberg, 2017, Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors, New England Journal of Medicine, 376, 125, 10.1056/NEJMoa1607427 Seregni, 2014, Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy, Eur. J. Nucl. Med. Mol. Imaging, 41, 223, 10.1007/s00259-013-2578-5 van Essen, 2008, Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours, Eur. J. Nucl. Med. Mol. Imaging, 35, 743, 10.1007/s00259-007-0688-7 Claringbold, 2016, Pancreatic Neuroendocrine Tumor Control: durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy, Neuroendocrinology, 103, 432, 10.1159/000434723 Bodei, 2016, Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors, Eur. J. Nucl. Med. Mol. Imaging, 43, 839, 10.1007/s00259-015-3250-z Lee, 2014, Targeted multimodal imaging modalities, Adv. Drug Deliv. Rev., 76, 60, 10.1016/j.addr.2014.07.009 Banerjee, 2001, Evolution of Tc-99m in diagnostic radiopharmaceuticals, Semin. Nucl. Med., 31, 260, 10.1053/snuc.2001.26205 Thakor, 2016, Clinically Approved Nanoparticle Imaging Agents, J. Nucl. Med., 57, 1833, 10.2967/jnumed.116.181362 Tong, 2011, Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging of cancer, Frontiers of Medicine, 5, 379, 10.1007/s11684-011-0162-6 Bobo, 2016, Nanoparticle-based Medicines: a Review of FDA-Approved Materials and Clinical Trials to date, Pharm. Res., 33, 2373, 10.1007/s11095-016-1958-5 Kinch, 2017, Analysis of FDA-approved imaging agents, Drug Discov. Today, 22, 1077, 10.1016/j.drudis.2017.03.006 Vats, 2017, Role of nanotechnology in theranostics and personalized medicines, Journal of Health Research and Reviews, 4, 1, 10.4103/2394-2010.199328 Jo, 2016, Targeted Nanotheranostics for Future Personalized Medicine: recent Progress in Cancer Therapy, Theranostics, 6, 1362, 10.7150/thno.15335 Ahn, 2016, Personalized Medicine based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer, Biomed. Res. Int., 2016, 1680464, 10.1155/2016/1680464 Jeelani, 2014, Theranostics: a treasured tailor for tomorrow, Journal of pharmacy & bioallied sciences, 6, S6, 10.4103/0975-7406.137249 Ottemann, 2018, Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities, Biomaterials, 185, 174, 10.1016/j.biomaterials.2018.09.018 Zhou, 2015, Toward Biocompatible Semiconductor Quantum Dots: from Biosynthesis and Bioconjugation to Biomedical Application, Chem. Rev., 115, 11669, 10.1021/acs.chemrev.5b00049 Dykman, 2012, Gold nanoparticles in biomedical applications: recent advances and perspectives, Chem. Soc. Rev., 41, 2256, 10.1039/C1CS15166E Xiaoming, 2016, Current investigations into magnetic nanoparticles for biomedical applications, Journal of Biomedical Materials Research Part A, 104, 1285, 10.1002/jbm.a.35654 Gao, 2009, Multifunctional magnetic Nanoparticles: Design, Synthesis, and Biomedical applications, Acc. Chem. Res., 42, 1097, 10.1021/ar9000026 Kevadiya, 2018, Multimodal Theranostic Nanoformulations Permit magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution, Theranostics, 8, 256, 10.7150/thno.22764 Buzea, 2007, Robbie, Nanomaterials and nanoparticles: sources and toxicity, Biointerphases, 2, Mr17, 10.1116/1.2815690 Bleeker, 2013, Considerations on the EU definition of a nanomaterial: Science to support policy making, Regul. Toxicol. Pharmacol., 65, 119, 10.1016/j.yrtph.2012.11.007 Muthu, 2014, Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics, Theranostics, 4, 660, 10.7150/thno.8698 Thanh, 2010, Functionalisation of nanoparticles for biomedical applications, Nano Today, 5, 213, 10.1016/j.nantod.2010.05.003 Li, 2015, Magnetic resonance imaging of folic acid-coated magnetite nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapy, Int. J. Nanomedicine, 10, 3779 Martinez-Skinner, 2015, Cellular responses and Tissue Depots for Nanoformulated Antiretroviral Therapy, PLoS One, 10, 10.1371/journal.pone.0145966 Puligujja, 2013, Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections, Nanomedicine, 9, 1263, 10.1016/j.nano.2013.05.003 Zhou, 2018, Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals, Nanomedicine, 13, 871, 10.2217/nnm-2017-0381 Kolhar, 2013, Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium, Proc. Natl. Acad. Sci., 110, 10753, 10.1073/pnas.1308345110 Wiley, 2013, Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor, Proc. Natl. Acad. Sci., 110, 8662, 10.1073/pnas.1307152110 Bhatia, 2016, 33 Gatoo, 2014, Physicochemical Properties of Nanomaterials: Implication in Associated toxic Manifestations, Biomed. Res. Int., 2014, 498420, 10.1155/2014/498420 Lindfors, 2006, Amorphous Drug Nanosuspensions. 1. Inhibition of Ostwald Ripening, Langmuir, 22, 906, 10.1021/la0523661 Sillman, 2018, Creation of a long-acting nanoformulated dolutegravir, Nat. Commun., 9, 443, 10.1038/s41467-018-02885-x Miao, 2018, Drug nanocrystals for cancer therapy, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 10 Rasenack, 2004, Micron-size Drug Particles: Common and Novel Micronization Techniques, Pharm. Dev. Technol., 9, 1, 10.1081/PDT-120027417 Kevadiya, 2018, Fenofibrate Nanocrystals embedded in Oral Strip-Films for Bioavailability Enhancement, Bioengineering, 5, 16, 10.3390/bioengineering5010016 Liu, 2015, The origin and function of tumor-associated macrophages, Cell Mol Immunol, 12, 1, 10.1038/cmi.2014.83 Lu, 2014, Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation, J. Control. Release, 176, 76, 10.1016/j.jconrel.2013.12.018 Pawar, 2014, Engineered nanocrystal technology: In-vivo fate, targeting and applications in drug delivery, J. Control. Release, 183, 51, 10.1016/j.jconrel.2014.03.030 Hollis, 2013, Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: Lessons learned of the EPR effect and image-guided drug delivery, J. Control. Release, 172, 12, 10.1016/j.jconrel.2013.06.039 Chen, 2016, Formulation of 20(S)-protopanaxadiol nanocrystals to improve oral bioavailability and brain delivery, Int. J. Pharm., 497, 239, 10.1016/j.ijpharm.2015.12.014 Roma, 2015, Tetronic® 904-containing polymeric micelles overcome the overexpression of ABCG2 in the blood–brain barrier of rats and boost the penetration of the antiretroviral efavirenz into the CNS, Nanomedicine, 10, 2325, 10.2217/nnm.15.77 Kreuter, 2014, Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?, Adv. Drug Deliv. Rev., 71, 2, 10.1016/j.addr.2013.08.008 Cheng, 2015, A holistic approach to targeting disease with polymeric nanoparticles, Nat. Rev. Drug Discov., 14, 239, 10.1038/nrd4503 Gerson, 2014, Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain, Nanomedicine, 10, 177, 10.1016/j.nano.2013.06.012 Bramini, 2014, Imaging Approach to Mechanistic Study of Nanoparticle Interactions with the Blood–Brain Barrier, ACS Nano, 8, 4304, 10.1021/nn5018523 Kulkarni, 2013, Effects of Particle size and Surface Modification on Cellular Uptake and Biodistribution of Polymeric Nanoparticles for Drug delivery, Pharm. Res., 30, 2512, 10.1007/s11095-012-0958-3 Gao, 2006, Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate-80coated polybutylcyanoacrylate nanoparticles, Int. J. Pharm., 310, 213, 10.1016/j.ijpharm.2005.11.040 Guarnieri, 2013, Shuttle-Mediated Nanoparticle delivery to the Blood–Brain Barrier, Small, 9, 853, 10.1002/smll.201201870 Cabezón, 2015, Trafficking of Gold Nanoparticles Coated with the 8D3 Anti-Transferrin Receptor Antibody at the Mouse Blood–Brain Barrier, Mol. Pharm., 12, 4137, 10.1021/acs.molpharmaceut.5b00597 Menéndez, 2002, A.n. Hidalgo, A. Baamonde, Unilateral hot plate test: a simple and sensitive method for detecting central and peripheral hyperalgesia in mice, J. Neurosci. Methods, 113, 91, 10.1016/S0165-0270(01)00483-6 Montesinos, 2014, Coadministration of P-Glycoprotein Modulators on Loperamide Pharmacokinetics and Brain distribution, Drug Metab. Dispos., 42, 700, 10.1124/dmd.113.055566 Fornaguera, 2015, PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood–brain barrier, J. Control. Release, 211, 134, 10.1016/j.jconrel.2015.06.002 Shinoda, 2007, Antihyperalgesic effects of loperamide in a model of rat neuropathic pain are mediated by peripheral δ-opioid receptors, Neurosci. Lett., 411, 143, 10.1016/j.neulet.2006.10.027 Li-Blatter, 2009, Detergents as intrinsic P-glycoprotein substrates and inhibitors, Biochim. Biophys. Acta Biomembr., 1788, 2335, 10.1016/j.bbamem.2009.07.010 Salvalaio, 2016, Targeted Polymeric Nanoparticles for Brain delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders, PLoS One, 11, 10.1371/journal.pone.0156452 Kozielski, 2014, Bioreducible Cationic Polymer-based Nanoparticles for Efficient and Environmentally Triggered Cytoplasmic siRNA delivery to primary Human Brain Cancer Cells, ACS Nano, 8, 3232, 10.1021/nn500704t Leiro, 2018, Dendrimers as Powerful Building Blocks in Central nervous System Disease: headed for successful Nanomedicine, Adv. Funct. Mater., 28, 1700313, 10.1002/adfm.201700313 Xu, 2014, Dendrimer advances for the Central nervous System delivery of Therapeutics, ACS Chem. Neurosci., 5, 2, 10.1021/cn400182z Shakhbazau, 2015, Fluorescent Phosphorus Dendrimer as a Spectral Nanosensor for Macrophage Polarization and Fate Tracking in Spinal Cord Injury, Macromolecular Bioscience, 15, 1523, 10.1002/mabi.201500150 Nance, 2014, Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood−brain barrier using MRI-guided focused ultrasound, J. Control. Release, 189, 123, 10.1016/j.jconrel.2014.06.031 Liu, 2014, Combining Microbubbles and Ultrasound for Drug delivery to Brain Tumors: Current Progress and Overview, Theranostics, 4, 432, 10.7150/thno.8074 Aryal, 2014, Ultrasound-mediated blood–brain barrier disruption for targeted drug delivery in the central nervous system, Adv. Drug Deliv. Rev., 72, 94, 10.1016/j.addr.2014.01.008 Koczera, 2017, PBCA-based polymeric microbubbles for molecular imaging and drug delivery, J. Control. Release, 259, 128, 10.1016/j.jconrel.2017.03.006 Allen, 2013, Liposomal drug delivery systems: from concept to clinical applications, Adv. Drug Deliv. Rev., 65, 36, 10.1016/j.addr.2012.09.037 Julia, 2017, Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases, Current Pharmaceutical Design, 23, 3120 Tapeinos, 2017, Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases, J. Control. Release, 264, 306, 10.1016/j.jconrel.2017.08.033 Cacciatore, 2016, Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases, Expert Opinion on Drug Delivery, 13, 1121, 10.1080/17425247.2016.1178237 Singh, 2014, Lymphatic system: a prospective area for advanced targeting of particulate drug carriers, Expert Opinion on Drug Delivery, 11, 211, 10.1517/17425247.2014.866088 Bae, 2013, Optically Traceable Solid Lipid Nanoparticles Loaded with siRNA and Paclitaxel for Synergistic Chemotherapy with in situ Imaging, Advanced Healthcare Materials, 2, 576, 10.1002/adhm.201200338 Torchilin, 2005, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov., 4, 145, 10.1038/nrd1632 Xu, 2018, Glioma-Targeted delivery of a Theranostic Liposome Integrated with Quantum Dots, Superparamagnetic Iron Oxide, and Cilengitide for Dual-Imaging Guiding Cancer Surgery, Advanced Healthcare Materials, 7, 1701130, 10.1002/adhm.201701130 Kizelsztein, 2004 Vedagiri, 2016, Mitigating effect of chrysin loaded solid lipid nanoparticles against Amyloid β25-35 induced oxidative stress in rat hippocampal region: an efficient formulation approach for Alzheimer's disease, Neuropeptides, 58, 111, 10.1016/j.npep.2016.03.002 Rassu, 2017, Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy, Colloids Surf. B: Biointerfaces, 152, 296, 10.1016/j.colsurfb.2017.01.031 Vieira, 2016, Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier, Int. J. Nanomedicine, 11, 5381, 10.2147/IJN.S117210 Lindqvist, 2016, In vivo Functional Evaluation of increased Brain delivery of the Opioid Peptide DAMGO by Glutathione-PEGylated Liposomes, Pharm. Res., 33, 177, 10.1007/s11095-015-1774-3 Gaillard, 2014, Pharmacokinetics, Brain delivery, and Efficacy in Brain Tumor-Bearing mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101), PLoS One, 9, 10.1371/journal.pone.0082331 Kenny, 2013, Multifunctional receptor-targeted nanocomplexes for the delivery of therapeutic nucleic acids to the Brain, Biomaterials, 34, 9190, 10.1016/j.biomaterials.2013.07.081 Zheng, 2015, Intranasal H102 Peptide-Loaded Liposomes for Brain delivery to Treat Alzheimer's Disease, Pharm. Res., 32, 3837, 10.1007/s11095-015-1744-9 Chen, 2017, Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug delivery Overcoming BBB and BBTB, ACS Appl. Mater. Interfaces, 9, 5864, 10.1021/acsami.6b15831 Sharma, 2013, Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: Biodistribution and transfection, J. Control. Release, 167, 1, 10.1016/j.jconrel.2013.01.016 Zhao, 2016, Dual targeted nanocarrier for brain ischemic stroke treatment, J. Control. Release, 233, 64, 10.1016/j.jconrel.2016.04.038 Gao, 2013, Glioma targeting and blood–brain barrier penetration by dual-targeting doxorubincin liposomes, Biomaterials, 34, 5628, 10.1016/j.biomaterials.2013.03.097 Hernando, 2018, Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease, Mol. Neurobiol., 55, 145, 10.1007/s12035-017-0728-7 Huang, 2015, GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer's Disease, ACS Nano, 9, 10801, 10.1021/acsnano.5b03124 Hong, 2018, Intense Red-Emitting Upconversion Nanophosphors (800 nm-Driven) with a Core/Double-Shell Structure for Dual-Modal Upconversion Luminescence and magnetic Resonance in Vivo Imaging applications, ACS Appl. Mater. Interfaces, 10, 12331, 10.1021/acsami.7b18078 Ehlerding, 2018, Big potential from Small Agents: Nanoparticles for Imaging-based Companion Diagnostics, ACS Nano, 12, 2106, 10.1021/acsnano.7b07252 Khlebtsov, 2013, Analytical and Theranostic applications of Gold Nanoparticles and Multifunctional Nanocomposites, Theranostics, 3, 167, 10.7150/thno.5716 Saraiva, 2016, Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases, J. Control. Release, 235, 34, 10.1016/j.jconrel.2016.05.044 Agyare, 2014, Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits, J. Control. Release, 185, 121, 10.1016/j.jconrel.2014.04.010 Dilnawaz, 2015, Therapeutic approaches of magnetic nanoparticles for the central nervous system, Drug Discov. Today, 20, 1256, 10.1016/j.drudis.2015.06.008 Busquets, 2014, Potential applications of magnetic particles to detect and treat Alzheimer's disease, Nanoscale Res. Lett., 9, 538, 10.1186/1556-276X-9-538 Niu, 2017, Inhibition by Multifunctional magnetic Nanoparticles Loaded with Alpha-Synuclein RNAi Plasmid in a Parkinson's Disease Model, Theranostics, 7, 344, 10.7150/thno.16562 Laurent, 2008, Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological applications, Chem. Rev., 108, 2064, 10.1021/cr068445e Amendola, 2011, Magnetic Nanoparticles of Iron Carbide, Iron Oxide, Iron@Iron Oxide, and Metal Iron Synthesized by Laser Ablation in Organic Solvents, J. Phys. Chem. C, 115, 5140, 10.1021/jp109371m Dai, 2014, One-pot facile synthesis of PEGylated superparamagnetic iron oxide nanoparticles for MRI contrast enhancement, Mater. Sci. Eng. C, 41, 161, 10.1016/j.msec.2014.04.041 Chen, 2013, Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo, Biomaterials, 34, 8798, 10.1016/j.biomaterials.2013.07.084 Betzer, 2017, The effect of nanoparticle size on the ability to cross the blood–brain barrier: an in vivo study, Nanomedicine, 12, 1533, 10.2217/nnm-2017-0022 Ruff, 2017, The effects of gold nanoparticles functionalized with ß-amyloid specific peptides on an in vitro model of blood-brain barrier, Nanomedicine, 13, 1645, 10.1016/j.nano.2017.02.013 Gao, 2016, Progress and perspectives on targeting nanoparticles for brain drug delivery, Acta Pharm. Sin. B, 6, 268, 10.1016/j.apsb.2016.05.013 Li, 2018, Delivery systems for theranostics in neurodegenerative diseases, Nano Res., 11, 5535, 10.1007/s12274-018-2067-z Leyva-Gómez, 2015, Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain, Drug Discov. Today, 20, 824, 10.1016/j.drudis.2015.02.009 Singh, 2012, Theranostic Implications of Nanotechnology in Multiple Sclerosis: a Future Perspective, Autoimmune Diseases, 2012, 160830, 10.1155/2012/160830 Bolognesi, 2016, From Companion Diagnostics to Theranostics: a New Avenue for Alzheimer's Disease?, J. Med. Chem., 59, 7759, 10.1021/acs.jmedchem.6b00151 Amiri, 2013, Alzheimer's Disease: Pathophysiology and applications of magnetic Nanoparticles as MRI Theranostic Agents, ACS Chem. Neurosci., 4, 1417, 10.1021/cn4001582 Ji, 2017, Combining nanoscale magnetic nimodipine liposomes with magnetic resonance image for Parkinson's disease targeting therapy, Nanomedicine, 12, 237, 10.2217/nnm-2016-0267 Pedram, 2016, Optimal magnetic Field for Crossing Super-Para-magnetic Nanoparticles through the Brain Blood Barrier: a Computational Approach, Biosensors, 6, 25, 10.3390/bios6020025 Kirschbaum, 2016, In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis, Proc. Natl. Acad. Sci., 113, 13227, 10.1073/pnas.1609397113 Yu, 2016, A multimodal Pepstatin a peptide-based nanoagent for the molecular imaging of P-glycoprotein in the brains of epilepsy rats, Biomaterials, 76, 173, 10.1016/j.biomaterials.2015.10.050 Lécuyer, 2016, Chemically engineered persistent luminescence nanoprobes for bioimaging, Theranostics, 6, 2488, 10.7150/thno.16589 Vilela, 2017, Graphene Oxide-Upconversion Nanoparticle based Optical Sensors for Targeted Detection of mRNA Biomarkers present in Alzheimer's Disease and Prostate Cancer, ACS Sensors, 2, 52, 10.1021/acssensors.6b00651 Cui, 2016, Sensitive imaging and effective capture of Cu2+: Towards highly efficient theranostics of Alzheimer's disease, Biomaterials, 104, 158, 10.1016/j.biomaterials.2016.06.056 Huang, 2015, Target-Triggered Switching on and off the Luminescence of Lanthanide Coordination Polymer Nanoparticles for Selective and Sensitive Sensing of Copper Ions in Rat Brain, Anal. Chem., 87, 6834, 10.1021/acs.analchem.5b01155 Zheng, 2015, Self-Targeting Fluorescent Carbon Dots for Diagnosis of Brain Cancer Cells, ACS Nano, 9, 11455, 10.1021/acsnano.5b05575 Kwon, 2016, Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer's Disease, ACS Nano, 10, 2860, 10.1021/acsnano.5b08045 Liu, 2018, Synergistic Inhibitory effect of GQDs–Tramiprosate Covalent Binding on Amyloid Aggregation, ACS Chem. Neurosci., 9, 817, 10.1021/acschemneuro.7b00439 Naz, 2017, Cerium oxide nanoparticles: a 'radical' approach to neurodegenerative disease treatment, Nanomedicine (Lond), 12, 545, 10.2217/nnm-2016-0399 Manne, 2015, Cerium Oxide Nanoparticles Confer Protection against Severe Sepsis Induced Hepatic Inflammation and Injury in Sprague Dawley Rats, FASEB J., 29, 620.613, 10.1096/fasebj.29.1_supplement.620.13 Estevez, 2011, Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia, Free Radic. Biol. Med., 51, 1155, 10.1016/j.freeradbiomed.2011.06.006 Schubert, 2006, Cerium and yttrium oxide nanoparticles are neuroprotective, Biochem. Biophys. Res. Commun., 342, 86, 10.1016/j.bbrc.2006.01.129 Das, 2013, Cerium oxide nanoparticles: applications and prospects in nanomedicine, Nanomedicine (Lond), 8, 1483, 10.2217/nnm.13.133 Zhao, 2016, Probing the molecular mechanism of cerium oxide nanoparticles in protecting against the neuronal cytotoxicity of a[small beta]1-42 with copper ions, Metallomics, 8, 644, 10.1039/C5MT00242G Hirst, 2013, Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice, Environ. Toxicol., 28, 107, 10.1002/tox.20704 Li, 2012, Using Graphene Oxide High Near-infrared Absorbance for Photothermal Treatment of Alzheimer's Disease, Adv. Mater., 24, 1722, 10.1002/adma.201104864 Li, 2017, Molybdenum disulfide nanosheets supported Au-Pd bimetallic nanoparticles for non-enzymatic electrochemical sensing of hydrogen peroxide and glucose, Sensors Actuators B Chem., 239, 536, 10.1016/j.snb.2016.08.048 Khan, 2017 Gupta, 2016, Bifunctional Luminomagnetic Rare-Earth Nanorods for High-Contrast Bioimaging Nanoprobes, Sci. Rep., 6, 32401, 10.1038/srep32401 Kevadiya, 2017, Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging, Acta Biomater., 49, 507, 10.1016/j.actbio.2016.11.071 Chen, 2014, Theranostic Nanoparticles, J. Nucl. Med., 55, 1919, 10.2967/jnumed.114.146019 Sintov, 2016, Chapter Six - Metal Nanoparticles as Targeted Carriers Circumventing the Blood–Brain Barrier, 199, 10.1016/bs.irn.2016.06.007 Ahmad, 2017, Nanotechnology based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective, Curr. Alzheimer Res., 14, 1164, 10.2174/1567205014666170508121031 Shadab, 2009, CNS Drug delivery Systems: Novel Approaches, Recent Patents on Drug Delivery & Formulation, 3, 71, 10.2174/187221109787158355 Sweeney, 2018, Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders, Nat. Rev. Neurol., 14, 133, 10.1038/nrneurol.2017.188 Lee, 2011, Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives, Neurosci. Res., 70, 339, 10.1016/j.neures.2011.05.008 Walker, 2012, Corruption and Spread of Pathogenic Proteins in Neurodegenerative Diseases, J. Biol. Chem., 287, 33109, 10.1074/jbc.R112.399378 Chánez-Cárdenas, 2012, The Aggregation of Huntingtin and α-Synuclein, Journal of Biophysics, 2012, 606172, 10.1155/2012/606172 Barry, 2013, Coupling Mechanical Forces to Electrical Signaling: Molecular Motors and the Intracellular Transport of Ion Channels, The Neuroscientist, 19, 145, 10.1177/1073858412456088 Wood, 2015, Systems biology of neurodegenerative diseases, Integr. Biol., 7, 758, 10.1039/C5IB00031A Gendelman, 2015, Nanoneuromedicines for Degenerative, Inflammatory, and Infectious Nervous System Diseases, Nanomedicine, 11, 751 Yacoubian, 2017, 1 Legname, 2015, 155 Agrawal, 2015, Molecular diagnostics of neurodegenerative disorders, Front. Mol. Biosci., 2, 54, 10.3389/fmolb.2015.00054 Chen, 2014, The Treatment strategies for Neurodegenerative Diseases by Integrative Medicine, Integrative Medicine International, 1, 223, 10.1159/000381546 Kiaei, 2013, New hopes and challenges for Treatment of Neurodegenerative Disorders: Great Opportunities for Young Neuroscientists, Basic and Clinical Neuroscience, 4, 3 Amor, 2010, Inflammation in neurodegenerative diseases, Immunology, 129, 154, 10.1111/j.1365-2567.2009.03225.x Bateman, 2012, J.C. Morris Clinical and Biomarker changes in Dominantly Inherited Alzheimer's Disease, N. Engl. J. Med., 367, 795, 10.1056/NEJMoa1202753 Demaagd, 2015, Parkinson's Disease and its Management: part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis, Pharmacy and Therapeutics, 40, 504 Dilokthornsakul, 2016, Multiple sclerosis prevalence in the United States commercially insured population, Neurology, 86, 1014, 10.1212/WNL.0000000000002469 Petrov, 2017, ALS Clinical Trials Review: 20 years of failure. Are we any closer to Registering a New Treatment?, Frontiers in Aging, Neuroscience, 9, 68 Roos, 2010, Huntington's disease: a clinical review, Orphanet Journal of Rare Diseases, 5, 1, 10.1186/1750-1172-5-40 Alzheimer's Association, 2018 McHale, 2016, Reclassifying neurodegenerative diseases to enable drug development and help patients, Research & Innovation News -Aetionomy, July, 1 Ramos-Cabrer, 2013, Liposomes and nanotechnology in drug development: focus on neurological targets, Int. J. Nanomedicine, 8, 951, 10.2147/IJN.S30721 Johnstone, 1999, A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced, J. Neuroimmunol., 93, 182, 10.1016/S0165-5728(98)00226-4 Wood, 2015, Systems biology of neurodegenerative diseases, Integrative Biology, 7, 758, 10.1039/C5IB00031A Zlokovic, 2008, The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders, Neuron, 57, 178, 10.1016/j.neuron.2008.01.003 Banks, 2008, Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease, BMC Neurosci., 9, S2, 10.1186/1471-2202-9-S3-S2 Ballabh, 2004, The blood–brain barrier: an overview: Structure, regulation, and clinical implications, Neurobiol. Dis., 16, 1, 10.1016/j.nbd.2003.12.016 Zhou, 2018, Crossing the blood-brain barrier with nanoparticles, J. Control. Release, 270, 290, 10.1016/j.jconrel.2017.12.015 Banks, 2012, Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier, Adv. Drug Deliv. Rev., 64, 629, 10.1016/j.addr.2011.12.005 Rodríguez, 2010, The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid, Peptides, 31, 757, 10.1016/j.peptides.2010.01.003 Neuwelt, 2008, Strategies to advance translational research into brain barriers, The Lancet Neurology, 7, 84, 10.1016/S1474-4422(07)70326-5 Walczyk, 2010, What the Cell “Sees” in Bionanoscience, J. Am. Chem. Soc., 132, 5761, 10.1021/ja910675v Aggarwal, 2009, Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy, Adv. Drug Deliv. Rev., 61, 428, 10.1016/j.addr.2009.03.009 Shah, 2012, Blood–Nanoparticle Interactions and in Vivo Biodistribution: Impact of Surface PEG and Ligand Properties, Mol. Pharm., 9, 2146, 10.1021/mp200626j Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat. Biotechnol., 33, 941, 10.1038/nbt.3330 Clark, 2015, Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core, Proc. Natl. Acad. Sci., 112, 12486, 10.1073/pnas.1517048112 Banks, 2009, Characteristics of compounds that cross the blood-brain barrier, BMC Neurol., 9, 1, 10.1186/1471-2377-9-S1-S3 Sarin, 2010, Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability, J. Angiogenes. Res., 2, 1, 10.1186/2040-2384-2-14 Duvernoy, 1983, The vascularization of the human cerebellar cortex, Brain Res. Bull., 11, 419, 10.1016/0361-9230(83)90116-8 Sharma, 2018, Physical characterization and in vivo organ distribution of coated iron oxide nanoparticles, Sci. Rep., 8, 4916, 10.1038/s41598-018-23317-2 Krol, 2012, Challenges in drug delivery to the brain: Nature is against us, J. Control. Release, 164, 145, 10.1016/j.jconrel.2012.04.044 Wohlfart, 2012, Transport of drugs across the blood–brain barrier by nanoparticles, J. Control. Release, 161, 264, 10.1016/j.jconrel.2011.08.017 Pardridge, 2005, The blood-brain barrier and neurotherapeutics, NeuroRx, 2, 1, 10.1602/neurorx.2.1.1 Grabrucker, 2016, Nanoparticle transport across the blood brain barrier, Tissue Barriers, 4, 10.1080/21688370.2016.1153568 Shah, 2013, Nanotechnology for CNS delivery of bio-therapeutic agents, Drug Delivery and Translational Research, 3, 336, 10.1007/s13346-013-0133-3 Gomes, 1757, J.d. Neves, B. Sarmento, Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system, Int. J. Nanomedicine, 9 Dube, 2017, Receptor Targeted Polymeric Nanostructures Capable of Navigating across the Blood-Brain Barrier for Effective delivery of Neural Therapeutics, ACS Chem. Neurosci., 8, 2105, 10.1021/acschemneuro.7b00207 Kabanov, 2007, Nanomedicine in the diagnosis and therapy of neurodegenerative disorders, Prog. Polym. Sci., 32, 1054, 10.1016/j.progpolymsci.2007.05.014 Wang, 2014, Caveolae-mediated delivery of Therapeutic Nanoparticles across Blood-endothelial Barrier, Austin Journal of Analytical and Pharmaceutical Chemistry, 1, 1018 Georgieva, 2011, Surface Characteristics of Nanoparticles Determine their Intracellular Fate in and Processing by Human Blood–Brain Barrier Endothelial Cells in Vitro, Mol. Ther., 19, 318, 10.1038/mt.2010.236 Conner, 2003, Regulated portals of entry into the cell, Nature, 422, 37, 10.1038/nature01451 Cheng, 2006, Membrane microdomains, caveolae, and caveolar endocytosis of sphingolipids (Review), Mol. Membr. Biol., 23, 101, 10.1080/09687860500460041 Wang, 2009, Size and Dynamics of Caveolae Studied using Nanoparticles in living Endothelial Cells, ACS Nano, 3, 4110, 10.1021/nn9012274 Xiao, 2013, Receptor-mediated endocytosis and brain delivery of therapeutic biologics, Int J Cell Biol, 2013, 703545, 10.1155/2013/703545 Kaksonen, 2018, Mechanisms of clathrin-mediated endocytosis, Nat. Rev. Mol. Cell Biol., 19, 313, 10.1038/nrm.2017.132 Traub, 2011, Regarding the Amazing Choreography of Clathrin Coats, PLoS Biol., 9, 10.1371/journal.pbio.1001037 Löscher, 2005, Blood-brain barrier active efflux transporters: ATP-binding cassette gene family, NeuroRx, 2, 86, 10.1602/neurorx.2.1.86 Dante, 2017, Selective Targeting of Neurons with Inorganic Nanoparticles: Revealing the crucial Role of Nanoparticle Surface Charge, ACS Nano, 11, 6630, 10.1021/acsnano.7b00397 Ulbrich, 2009, Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB), Eur. J. Pharm. Biopharm., 71, 251, 10.1016/j.ejpb.2008.08.021 Jallouli, 2007, Influence of surface charge and inner composition of porous nanoparticles to cross blood–brain barrier in vitro, Int. J. Pharm., 344, 103, 10.1016/j.ijpharm.2007.06.023 Gao, 2014, Overcoming the Blood–Brain Barrier for Delivering Drugs into the Brain by using Adenosine Receptor Nanoagonist, ACS Nano, 8, 3678, 10.1021/nn5003375 Schnyder, 2005, Drug Transport to Brain with Targeted Liposomes, NeuroRx, 2, 99, 10.1602/neurorx.2.1.99 Hersh, 2016, Evolving Drug delivery strategies to Overcome the Blood Brain Barrier, Curr. Pharm. Des., 22, 1177, 10.2174/1381612822666151221150733 Jain, 2012, Nanobiotechnology-based strategies for crossing the blood-brain barrier, Nanomedicine (Lond), 7, 1225, 10.2217/nnm.12.86 Lohmann, 2012, Identification of PSEN1 and PSEN2 gene mutations and variants in Turkish dementia patients, Neurobiology of Aging, 33, 1850.e1817, 10.1016/j.neurobiolaging.2012.02.020 Stelzmann, 1995, An english translation of alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde”, Clin. Anat., 8, 429, 10.1002/ca.980080612 Magalingam, 2018, Current Concepts of Neurodegenerative Mechanisms in Alzheimers Disease, Biomed. Res. Int., 2018, 12, 10.1155/2018/3740461 Hebert, 2013, Alzheimer disease in the United States (2010–2050) estimated using the 2010 census, Neurology, 80, 1778, 10.1212/WNL.0b013e31828726f5 New Analysis Shows More Than 28 Million Baby Boomers Will Develop Alzheimer's Disease, 2015 von Strauss, 1999, Aging and the occurrence of dementia: Findings from a population-based cohort with a large sample of nonagenarians, Arch. Neurol., 56, 587, 10.1001/archneur.56.5.587 Brookmeyer, 2007, Forecasting the global burden of Alzheimer's disease, Alzheimers Dement., 3, 186, 10.1016/j.jalz.2007.04.381 2018 Alzheimer's disease facts and figures, Alzheimer's & Dementia, 14 (2018) 367–429. Qiu, 2009, Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention, Dialogues Clin. Neurosci., 11, 111, 10.31887/DCNS.2009.11.2/cqiu Minati, 2009, Current concepts in Alzheimer's disease: a multidisciplinary review, Am J Alzheimers Dis Other Demen, 24, 95, 10.1177/1533317508328602 Groves-Wright, 2004, A comparison of verbal and written language in Alzheimer's disease, J. Commun. Disord., 37, 109, 10.1016/j.jcomdis.2003.08.004 Mega, 1996, The spectrum of behavioral changes in Alzheimer's disease, Neurology, 46, 130, 10.1212/WNL.46.1.130 Hane, 2017, Recent Progress in Alzheimer's Disease Research, part 3: Diagnosis and Treatment, J. Alzheimers Dis., 57, 645, 10.3233/JAD-160907 Dubois, 2007, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria, The Lancet Neurology, 6, 734, 10.1016/S1474-4422(07)70178-3 McKhann, 2011, The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, 263, 10.1016/j.jalz.2011.03.005 Kelley, 2007, Alzheimer's Disease and Mild Cognitive Impairment, Neurologic Clinics, 25, 577, 10.1016/j.ncl.2007.03.008 Hyman, 2012, National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease, Alzheimer's & dementia : the journal of the Alzheimer's Association, 8, 1, 10.1016/j.jalz.2011.10.007 Nisbet, 2015, Tau aggregation and its interplay with amyloid-β, Acta Neuropathol., 129, 207, 10.1007/s00401-014-1371-2 Spires-Jones, 2014, The intersection of amyloid beta and tau at synapses in Alzheimer's disease, Neuron, 82, 756, 10.1016/j.neuron.2014.05.004 Iqbal, 2005, Tau pathology in Alzheimer disease and other tauopathies, Biochimica et Biophysica Acta, 1739, 198, 10.1016/j.bbadis.2004.09.008 Zhang, 2015, Neuroinflammation in Alzheimer's disease, Neuropsychiatr. Dis. Treat., 11, 243, 10.2147/NDT.S75546 Bali, 2010, Cellular basis of Alzheimer's disease, Annals of Indian Academy of Neurology, 13, S89, 10.4103/0972-2327.74251 Brion, 1998, Neurofibrillary tangles and Alzheimer's disease, Eur. Neurol., 40, 130, 10.1159/000007969 Murray, 2014, Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis, Journal of Alzheimer's disease : JAD, 39, 759, 10.3233/JAD-131166 Serrano-Pozo, 2011, Neuropathological Alterations in Alzheimer Disease, Cold Spring Harbor Perspectives in Medicine, 1, a006189, 10.1101/cshperspect.a006189 Nalivaeva, 2013, The amyloid precursor protein: a biochemical enigma in brain development, function and disease, FEBS Lett., 587, 2046, 10.1016/j.febslet.2013.05.010 Dawkins, 2014, Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer's disease, J. Neurochem., 129, 756, 10.1111/jnc.12675 Young-Pearse, 2007, A critical Function for β-Amyloid Precursor Protein in Neuronal Migration Revealed by in Utero RNA Interference, J. Neurosci., 27, 14459, 10.1523/JNEUROSCI.4701-07.2007 Chow, 2010, An Overview of APP Processing Enzymes and Products, NeuroMolecular Med., 12, 1, 10.1007/s12017-009-8104-z Mockett, 2017 Golde, 2000, Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease, Biochimica et Biophysica Acta, 1502, 172, 10.1016/S0925-4439(00)00043-0 Lucey, 2014, Amyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis, Neurobiol. Aging, 35, S29, 10.1016/j.neurobiolaging.2014.03.035 Bekris, 2010, Genetics of Alzheimer Disease, J. Geriatr. Psychiatry Neurol., 23, 213, 10.1177/0891988710383571 Murphy, 2010, Alzheimer's Disease and the β-Amyloid Peptide, Journal of Alzheimer's Disease, 19, 311, 10.3233/JAD-2010-1221 Canevari, 1999, β-Amyloid fragment 25–35 selectively decreases complex IV activity in isolated mitochondria, FEBS Lett., 457, 131, 10.1016/S0014-5793(99)01028-5 Lin, 2001, Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology, FASEB J., 15, 2433, 10.1096/fj.01-0377com Rosales-Corral, 2004, Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-β onto the hippocampus in vivo, Journal of Neuroimmunology, 150, 20, 10.1016/j.jneuroim.2004.01.005 Butterfield, 2007, Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment, Free Radic. Biol. Med., 43, 658, 10.1016/j.freeradbiomed.2007.05.037 Parameshwaran, 2008, Amyloid beta peptides and glutamatergic synaptic dysregulation, Exp. Neurol., 210, 7, 10.1016/j.expneurol.2007.10.008 Li, 2016, The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model, Nat. Commun., 7, 12082, 10.1038/ncomms12082 Rajmohan, 2017, Amyloid Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons, Journal of Alzheimer's Disease, 57, 975, 10.3233/JAD-160612 Simic, 2016, Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and possible Neuroprotective strategies, Biomol. Ther., 6, 6 Mietelska-Porowska, 2014, Tau Protein modifications and Interactions: their Role in Function and Dysfunction, Int. J. Mol. Sci., 15, 4671, 10.3390/ijms15034671 Jouanne, 2017, Tau protein aggregation in Alzheimer's disease: an attractive target for the development of novel therapeutic agents, Eur. J. Med. Chem., 139, 153, 10.1016/j.ejmech.2017.07.070 Wang, 2015, Tau in physiology and pathology, Nat. Rev. Neurosci., 17, 22, 10.1038/nrn.2015.1 Liu, 2013, Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy, Nat. Rev. Neurol., 9, 106, 10.1038/nrneurol.2012.263 Huang, 2004, Apolipoprotein E, J. Mol. Neurosci., 23, 189, 10.1385/JMN:23:3:189 Namba, 1991, Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease, Brain Res., 541, 163, 10.1016/0006-8993(91)91092-F Saunders, 1993, Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease, Neurology, 43, 1467, 10.1212/WNL.43.8.1467 Nagy, 1995, Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease, Neuroscience, 69, 757, 10.1016/0306-4522(95)00331-C Conejero-Goldberg, 2014, APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms, Mol. Psychiatry, 19, 1243, 10.1038/mp.2013.194 Berlau, 2009, APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old, Neurology, 72, 829, 10.1212/01.wnl.0000343853.00346.a4 Farrer, 1997, Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and alzheimer disease: a meta-analysis, JAMA, 278, 1349, 10.1001/jama.1997.03550160069041 Demattos, 2004, ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition: evidence that ApoE Regulates Extracellular Aβ Metabolism in Vivo, Neuron, 41, 193, 10.1016/S0896-6273(03)00850-X Hartmann, 1999, Intracellular biology of Alzheimer's disease amyloid beta peptide, Eur. Arch. Psychiatry Clin. Neurosci., 249, 291, 10.1007/s004060050102 Cummings, 2014, Alzheimer's disease drug-development pipeline: few candidates, frequent failures, Alzheimers Res. Ther., 6, 37, 10.1186/alzrt269 Dong, 2008, Effects of Memantine on Neuronal Structure and Conditioned fear in the Tg2576 Mouse Model of Alzheimer's Disease, Neuropsychopharmacology, 33, 3226, 10.1038/npp.2008.53 Anderson, 2017, Why do so many clinical trials of therapies for Alzheimer's disease fail?, Lancet, 390, 2327, 10.1016/S0140-6736(17)32399-1 Robert, 2008, Alzheimers Disease Drug Development in 2008 and beyond: Problems and Opportunities, Curr. Alzheimer Res., 5, 346, 10.2174/156720508785132299 Becker, 2013, A new roadmap for drug development for Alzheimer disease, Nat. Rev. Drug Discov., 13, 156, 10.1038/nrd3842-c2 Becker, 2008, Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?, Journal of Alzheimer's Disease, 15, 303, 10.3233/JAD-2008-15213 Pardridge, 2003, Blood-brain barrier drug targeting: the future of brain drug development, Mol. Interv., 3, 90, 10.1124/mi.3.2.90 Mulik, 2010, ApoE3 Mediated Poly(butyl) Cyanoacrylate Nanoparticles Containing Curcumin: Study of Enhanced activity of Curcumin against Beta Amyloid Induced Cytotoxicity using in Vitro Cell Culture Model, Mol. Pharm., 7, 815, 10.1021/mp900306x Doggui, 2012, Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line, Journal of Alzheimer's disease : JAD, 30, 377, 10.3233/JAD-2012-112141 Mathew, 2012, Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease, PLoS One, 7, 10.1371/journal.pone.0032616 Tokuraku, 2010, Real-Time Imaging and Quantification of Amyloid-β Peptide Aggregates by Novel Quantum-Dot Nanoprobes, PLoS One, 4 Zaim, 2003, Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging, Magnetic Resonance in Medicine, 50, 293, 10.1002/mrm.10529 Choi, 2008, Nanoparticle assisted magnetic resonance imaging of the early reversible stages of amyloid [small beta] self-assembly, Chem. Commun., 2197, 10.1039/b803294g Zhang, 2015, The detection of β-amyloid plaques in an Alzheimer's disease rat model with DDNP-SPIO, Clin. Radiol., 70, 74, 10.1016/j.crad.2014.09.019 Jaruszewski, 2014, Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain, Biomaterials, 35, 1967, 10.1016/j.biomaterials.2013.10.075 Zhang, 2014, Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice, Biomaterials, 35, 456, 10.1016/j.biomaterials.2013.09.063 Yiannopoulou, 2013, Current and future treatments for Alzheimer's disease, Ther. Adv. Neurol. Disord., 6, 19, 10.1177/1756285612461679 Santiago, 2017, Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology, Front. Aging Neurosci., 9, 166, 10.3389/fnagi.2017.00166 Khan, 2015, Early diagnosis of Alzheimer's disease using machine learning techniques: A review paper, 380 Shankar, 2009, Alzheimer's disease: synaptic dysfunction and Aβ, Mol. Neurodegener., 4, 1, 10.1186/1750-1326-4-48 Noble, 2009, Application of PET imaging to diagnosis of Alzheimer's disease and mild cognitive impairment, Int. Rev. Neurobiol., 84, 133, 10.1016/S0074-7742(09)00407-3 Mapstone, 2014, Plasma phospholipids identify antecedent memory impairment in older adults, Nat. Med., 20, 415, 10.1038/nm.3466 Segovia, 2014, Combining PET Images and Neuropsychological Test Data for Automatic Diagnosis of Alzheimer's Disease, PLoS One, 9, 10.1371/journal.pone.0088687 Hampel, 2004, CSF tau and β-amyloid as biomarkers for mild cognitive impairment, Dialogues Clin. Neurosci., 6, 379, 10.31887/DCNS.2004.6.4/hhampel Perrin, 2009, Multi-modal techniques for diagnosis and prognosis of Alzheimer's disease, Nature, 461, 916, 10.1038/nature08538 Álvarez, 2018, Gold Nanoparticles as Nucleation Centers for Amyloid Fibrillation, 269 Zhu, 2014, PET/SPECT imaging agents for neurodegenerative diseases, Chem. Soc. Rev., 43, 6683, 10.1039/C3CS60430F Choe, 2015, PET Radioligands for Imaging of Tau Pathology: Current Status, Nucl. Med. Mol. Imaging, 49, 251, 10.1007/s13139-015-0374-9 Stoessl, 2012, Neuroimaging in the early diagnosis of neurodegenerative disease, Translational Neurodegeneration, 1, 1, 10.1186/2047-9158-1-5 Skaat, 2009, Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-β fibrils detection and removal by a magnetic field, Biochem. Biophys. Res. Commun., 386, 645, 10.1016/j.bbrc.2009.06.110 Bingbing, 2015, Nanotheranostics: Congo Red/Rutin-MNPs with Enhanced magnetic Resonance Imaging and H2O2-Responsive Therapy of Alzheimer's Disease in APPswe/PS1dE9 Transgenic mice, Adv. Mater., 27, 5499, 10.1002/adma.201502227 Cheng, 2015, Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer's disease mice using magnetic resonance imaging (MRI), Biomaterials, 44, 155, 10.1016/j.biomaterials.2014.12.005 Nasr, 2018, Detection of β-Amyloid by Sialic Acid Coated Bovine Serum Albumin magnetic Nanoparticles in a Mouse Model of Alzheimer's Disease, Small, 14, 1701828, 10.1002/smll.201701828 Viola, 2014, Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease, Nat. Nanotechnol., 10, 91, 10.1038/nnano.2014.254 Yang, 2011, Detection of amyloid plaques targeted by USPIO-Aβ1–42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging, NeuroImage, 55, 1600, 10.1016/j.neuroimage.2011.01.023 Koffie, 2011, Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging, Proc. Natl. Acad. Sci., 108, 18837, 10.1073/pnas.1111405108 Tanifum, 2016, A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by magnetic Resonance Imaging, Journal of Alzheimer's Disease, 52, 731, 10.3233/JAD-151124 Mosconi, 2010, Pre-Clinical Detection of Alzheimer's Disease using FDG-PET, with or without Amyloid Imaging, Journal of Alzheimer's Disease, 20, 843, 10.3233/JAD-2010-091504 Sehlin, 2016, Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease, Nat. Commun., 7, 10759, 10.1038/ncomms10759 Chen, 2018, Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease, ACS Nano, 12, 1321, 10.1021/acsnano.7b07625 Zhang, 2018, Oligoethyleneoxy-Modified 99mTc-labeled β-Amyloid Imaging Probes with improved Brain Pharmacokinetics for Single-Photon Emission Computed Tomography, J. Med. Chem., 61, 1330, 10.1021/acs.jmedchem.7b01834 Coimbra, 2006, The role of MRI and PET/SPECT in Alzheimer's disease, Curr. Top. Med. Chem., 6, 629, 10.2174/156802606776743075 Humpel, 2011, Identifying and validating biomarkers for Alzheimer's disease, Trends Biotechnol., 29, 26, 10.1016/j.tibtech.2010.09.007 Yang, 2011, Biofunctionalized magnetic Nanoparticles for specifically Detecting Biomarkers of Alzheimer's Disease in Vitro, ACS Chem. Neurosci., 2, 500, 10.1021/cn200028j Neely, 2009, Ultrasensitive and Highly Selective Detection of Alzheimer's Disease Biomarker using Two-Photon Rayleigh Scattering Properties of Gold Nanoparticle, ACS Nano, 3, 2834, 10.1021/nn900813b Wang, 2012, Gold nanoparticle based dot-blot immunoassay for sensitively detecting Alzheimer's disease related [small beta]-amyloid peptide, Chem. Commun., 48, 8392, 10.1039/c2cc33568a Stegurová, 2014, Gold nanoparticle-based immuno-PCR for detection of tau protein in cerebrospinal fluid, J. Immunol. Methods, 406, 137, 10.1016/j.jim.2014.03.007 Tanifum, 2012, Intravenous delivery of targeted liposomes to amyloid-beta pathology in APP/PSEN1 transgenic mice, PLoS One, 7, 10.1371/journal.pone.0048515 Shui, 2018, Biosensors for Alzheimer's disease biomarker detection: a review, Biochimie, 147, 13, 10.1016/j.biochi.2017.12.015 Kim, 2018, A shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer's disease biomarkers, Biosens. Bioelectron., 101, 96, 10.1016/j.bios.2017.10.018 Vestergaard, 2008, Detection of Alzheimer's tau protein using localised surface plasmon resonance-based immunochip, Talanta, 74, 1038, 10.1016/j.talanta.2007.06.009 Hegnerová, 2009, Surface plasmon resonance biosensors for detection of Alzheimer disease biomarker, Sensors Actuators B Chem., 139, 69, 10.1016/j.snb.2008.09.006 Lisi, 2017, Toward sensitive immuno-based detection of tau protein by surface plasmon resonance coupled to carbon nanostructures as signal amplifiers, Biosens. Bioelectron., 93, 289, 10.1016/j.bios.2016.08.078 Wen, 2018, Amyloid beta-Derived Diffusible Ligands (ADDLs) Induce Abnormal Autophagy Associated with Abeta Aggregation Degree, J. Mol. Neurosci., 64, 162, 10.1007/s12031-017-1015-9 Georganopoulou, 2005, Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 102, 2273, 10.1073/pnas.0409336102 Qu, 2016, Dual Signal Amplification Electrochemical Biosensor for monitoring the activity and Inhibition of the Alzheimer's Related Protease β-Secretase, Anal. Chem., 88, 10559, 10.1021/acs.analchem.6b02659 Liu, 2012, A Highly Sensitive Gold-Nanoparticle-based Assay for Acetylcholinesterase in Cerebrospinal Fluid of Transgenic mice with Alzheimer's Disease, Advanced Healthcare Materials, 1, 90, 10.1002/adhm.201100002 Leszek, 2017, Nanotechnology for Alzheimer Disease, Curr. Alzheimer Res., 14, 1182, 10.2174/1567205014666170203125008 Liu, 2009, Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease, Neurosci. Lett., 455, 187, 10.1016/j.neulet.2009.03.064 Jesse, 2005, In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers, Angewandte Chemie International Edition, 44, 5452, 10.1002/anie.200500845 Fernández, 2018, Functionalization and Characterization of magnetic Nanoparticles for the Detection of Ferritin Accumulation in Alzheimer's Disease, ACS Chem. Neurosci., 9, 912, 10.1021/acschemneuro.7b00260 Amin, 2017, Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease, Nanoscale, 9, 10619, 10.1039/C7NR00772H Sun, 2018, Sulfur Nanoparticles with Novel Morphologies coupled with Brain-Targeting Peptides RVG as a New Type of Inhibitor against Metal-Induced Aβ Aggregation, ACS Chem. Neurosci., 9, 749, 10.1021/acschemneuro.7b00312 Heckman, 2013, Custom Cerium Oxide Nanoparticles Protect against a Free Radical Mediated Autoimmune Degenerative Disease in the Brain, ACS Nano, 7, 10582, 10.1021/nn403743b Yang, 2017, Dual-functional selenium nanoparticles bind to and inhibit amyloid [small beta] fiber formation in Alzheimer's disease, J. Mater. Chem. B, 5, 5954, 10.1039/C6TB02952C Ray, 2011, Neuroprotective and Neurorescue Effects of a Novel Polymeric Nanoparticle Formulation of Curcumin (NanoCurc™) in the Neuronal Cell Culture and Animal Model: Implications for Alzheimer's Disease, J. Alzheimers Dis., 23, 61, 10.3233/JAD-2010-101374 Luo, 2018, A self-destructive nanosweeper that captures and clears amyloid β-peptides, Nat. Commun., 9, 1802, 10.1038/s41467-018-04255-z Kuo, 2018, Use of functionalized liposomes loaded with antioxidants to permeate the blood–brain barrier and inhibit β-amyloid-induced neurodegeneration in the brain, J. Taiwan Inst. Chem. Eng., 87, 1, 10.1016/j.jtice.2018.03.001 Costa, 2016, Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative stress and more, Oxidative Med. Cell. Longev., 2016, 2986796, 10.1155/2016/2986796 Bana, 2014, Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood–brain-barrier: Implications for therapy of Alzheimer disease, Nanomedicine, 10, 1583, 10.1016/j.nano.2013.12.001 Farr, 2014, Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease, Free Radic. Biol. Med., 67, 387, 10.1016/j.freeradbiomed.2013.11.014 Devos, 2017 van Dyck, 2018, Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: pitfalls and Promise, Biol. Psychiatry, 83, 311, 10.1016/j.biopsych.2017.08.010 Prins, 2013, Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future, Alzheimers Res. Ther., 5, 56, 10.1186/alzrt220 Banks, 2007, Anti-amyloid beta protein antibody passage across the blood–brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment, Exp. Neurol., 206, 248, 10.1016/j.expneurol.2007.05.005 Banks, 2005, Effects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins, Peptides, 26, 287, 10.1016/j.peptides.2004.09.016 Finke, 2017, Antibody blood-brain barrier efflux is modulated by glycan modification, Biochim. Biophys. Acta Gen. Subj., 1861, 2228, 10.1016/j.bbagen.2017.06.008 Parkinson, 2002, An Essay on the Shaking Palsy, The Journal of Neuropsychiatry and Clinical Neurosciences, 14, 223, 10.1176/jnp.14.2.223 Pearce, 1989, Aspects of the history of Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 52, 6, 10.1136/jnnp.52.Suppl.6 Zeng, 2018, Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease, Front. Aging Neurosci., 10, 109, 10.3389/fnagi.2018.00109 Surmeier, 2010, Chapter 4 - What causes the death of dopaminergic neurons in Parkinson's disease?, 59, 10.1016/S0079-6123(10)83004-3 Alexander, 2004, Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder, Dialogues Clin. Neurosci., 6, 259, 10.31887/DCNS.2004.6.3/galexander Ferrer, 2011, Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease, J. Neural Transm., 118, 821, 10.1007/s00702-010-0482-8 Poewe, 2017, Parkinson disease, Nature Reviews Disease Primers, 3, 17013, 10.1038/nrdp.2017.13 Ascherio, 2016, The epidemiology of Parkinson's disease: risk factors and prevention, The Lancet Neurology, 15, 1257, 10.1016/S1474-4422(16)30230-7 Polymeropoulos, 1997, Mutation in the α-Synuclein Gene Identified in families with Parkinson's Disease, Science, 276, 2045, 10.1126/science.276.5321.2045 Karampetsou, 2017, Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice, Sci. Rep., 7, 16533, 10.1038/s41598-017-15813-8 Hoenen, 2016, Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: stronger Effects of the A53T Mutant, PLoS One, 11, 10.1371/journal.pone.0162717 Steger, 2017, Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis, elife, 6, 10.7554/eLife.31012 Bekris, 2010, The Genetics of Parkinson Disease, J. Geriatr. Psychiatry Neurol., 23, 228, 10.1177/0891988710383572 Hatcher, 2008, Parkinson's disease and pesticides: a toxicological perspective, Trends Pharmacol. Sci., 29, 322, 10.1016/j.tips.2008.03.007 Farrer, 2006, Genetics of Parkinson disease: paradigm shifts and future prospects, Nat. Rev. Genet., 7, 306, 10.1038/nrg1831 Davis, 1979, Chronic Parkinsonism secondary to intravenous injection of meperidine analogues, Psychiatry Res., 1, 249, 10.1016/0165-1781(79)90006-4 William Langston, 1984, Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey, Brain Res., 292, 390, 10.1016/0006-8993(84)90777-7 Langston, 1983, Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219, 979, 10.1126/science.6823561 Burke, 2013, Axon Degeneration in Parkinson's Disease, Exp. Neurol., 246, 72, 10.1016/j.expneurol.2012.01.011 Herkenham, 1991, Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study, Neuroscience, 40, 133, 10.1016/0306-4522(91)90180-V Heikkila, 1984, Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice, Science, 224, 1451, 10.1126/science.6610213 Jenner, 2008, Functional models of Parkinson's disease: a valuable tool in the development of novel therapies, Ann. Neurol., 64, S16 Di Monte, 1986, Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity, Biochem. Biophys. Res. Commun., 137, 303, 10.1016/0006-291X(86)91210-6 Betarbet, 2000, Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nat. Neurosci., 3, 1301, 10.1038/81834 Demaagd, 2015, Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents, Pharmacy and Therapeutics, 40, 590 Lewitt, 2016, Levodopa therapy for Parkinson disease, A look backward and forward, 86, S3 Olanow, 2006, Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications, The Lancet Neurology, 5, 677, 10.1016/S1474-4422(06)70521-X Müller, 2015, Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease, Drugs, 75, 157, 10.1007/s40265-014-0343-0 Schapira, 2011, Monoamine Oxidase B Inhibitors for the Treatment of Parkinson's Disease, CNS Drugs, 25, 1061, 10.2165/11596310-000000000-00000 Bronstein, 2011, Deep brain stimulation for parkinson disease: an expert consensus and review of key issues, Arch. Neurol., 68, 165, 10.1001/archneurol.2010.260 Eduardo, 2003, Clinical overview of the synucleinopathies, Movement Disorders, 18, 21, 10.1002/mds.10559 Jellinger, 2009, A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis., 1792, 730, 10.1016/j.bbadis.2008.07.006 Kaufmann, 2017, The Natural history of Pure Autonomic failure: a U.S. prospective Cohort, Ann. Neurol., 81, 287, 10.1002/ana.24877 Singer, 2017, Pure autonomic failure, Predictors of conversion to clinical CNS involvement, 88, 1129 Kaufmann, 2003, Autonomic failure in neurodegenerative disorders, Semin. Neurol., 23, 351, 10.1055/s-2004-817719 Kao, 2009, Cognitive and Neuropsychiatric Profile of the Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies and Multiple System Atrophy, Alzheimer disease and associated disorders, 23, 365 Blanc, 2015, Cortical Thickness in Dementia with Lewy Bodies and Alzheimer's Disease: a Comparison of Prodromal and Dementia Stages, PLoS One, 10, 10.1371/journal.pone.0127396 Gomperts, 2016, Lewy Body Dementias: Dementia with Lewy Bodies and Parkinson Disease Dementia, Continuum : Lifelong Learning in Neurology, 22, 435 Martí, 2003, Clinical overview of the synucleinopathies, Mov. Disord., 18, 21, 10.1002/mds.10559 Miraglia, 2015, Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge, Cent. Nerv. Syst. Agents Med. Chem., 15, 109, 10.2174/1871524915666150421114338 Huang, 2013, Angiopep-Conjugated Nanoparticles for Targeted Long-Term Gene Therapy of Parkinson's Disease, Pharm. Res., 30, 2549, 10.1007/s11095-013-1005-8 Biplob, 2006, Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys, Annals of Neurology, 60, 706, 10.1002/ana.21032 Bartus, 2017, Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: where have we been and what have we learned?, Neurobiol. Dis., 97, 156, 10.1016/j.nbd.2016.03.027 Bartus, 2017, Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: where do we stand and where must we go next?, Neurobiol. Dis., 97, 169, 10.1016/j.nbd.2016.03.026 Loane, 2011, Positron emission tomography neuroimaging in Parkinson's disease, Am. J. Transl. Res., 3, 323 Ito, 1999, Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 66, 754, 10.1136/jnnp.66.6.754 Antonini, 1995, Complementary positron emission tomographic studies of the striatal dopaminergic system in parkinsons disease, Arch. Neurol., 52, 1183, 10.1001/archneur.1995.00540360061017 Jacobs, 2005, Imaging in Neurooncology, NeuroRx, 2, 333, 10.1602/neurorx.2.2.333 Khan, 2002, Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study, Brain, 125, 2248, 10.1093/brain/awf237 Ba, 2015, Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice, Parkinsonism Relat. Disord., 21, 87, 10.1016/j.parkreldis.2014.11.007 Catafau, 2004, Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes, Mov. Disord., 19, 1175, 10.1002/mds.20112 McDonagh, 2016, L-DOPA-Coated Manganese Oxide Nanoparticles as dual MRI Contrast Agents and Drug-delivery Vehicles, Small, 12, 301, 10.1002/smll.201502545 Li, 2012, Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective, J. Neurol. Sci., 317, 1, 10.1016/j.jns.2012.02.018 Salahuddin, 2014, The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach, Cellular & Molecular Biology Letters, 19, 407, 10.2478/s11658-014-0205-5 Byun, 2017, Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases, Pharmacol. Ther., 177, 44, 10.1016/j.pharmthera.2017.02.030 Bayarsaikhan, 2015, Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics, Int. J. Nanomedicine, 10, 281 Katzenschlager, 2002, Treatment of Parkinson's disease: levodopa as the first choice, Journal of Neurology, 249, ii19, 10.1007/s00415-002-1204-4 Stocchi, 2005, Optimising levodopa therapy for the management of Parkinson's disease, J Neurol, 252, Iv43 Mead, 2017, Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model, Nano Lett., 17, 3533, 10.1021/acs.nanolett.7b00616 Wen, 2011, Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration, J. Control. Release, 151, 131, 10.1016/j.jconrel.2011.02.022 Hu, 2011, Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson's disease, Int. J. Pharm., 415, 273, 10.1016/j.ijpharm.2011.05.062 Pahuja, 2015, Trans-Blood Brain Barrier delivery of Dopamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Rats, ACS Nano, 9, 4850, 10.1021/nn506408v Raj, 2018, Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity, Int. J. Biol. Macromol., 109, 27, 10.1016/j.ijbiomac.2017.12.056 Chung, 2018, Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson's disease, Nanoscale, 10, 2998, 10.1039/C7NR06976F Hu, 2018, Neuroprotective effect of gold nanoparticles composites in Parkinson's disease model, Nanomedicine, 14, 1123, 10.1016/j.nano.2018.01.020 Dranka, 2014, A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2R1441G) transgenic mouse model of Parkinson's disease, Neurosci. Lett., 583, 159, 10.1016/j.neulet.2014.09.042 Ghosh, 2012, Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease, J. Neuroinflammation, 9, 241, 10.1186/1742-2094-9-241 Jin, 2008, Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats, Eur. J. Pharmacol., 600, 78, 10.1016/j.ejphar.2008.10.005 Palle, 2018, Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson's disease, Naunyn Schmiedeberg's Arch. Pharmacol., 391, 445, 10.1007/s00210-018-1474-8 Brenza, 2017, Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy, Nanomedicine, 13, 809, 10.1016/j.nano.2016.10.004 Imran, 2011, An overview of human prion diseases, Virol. J., 8, 1 Jucker, 2013, Self-propagation of pathogenic protein aggregates in neurodegenerative diseases, Nature, 501, 45, 10.1038/nature12481 Dearmond, 2004, Discovering the Mechanisms of Neurodegeneration in Prion Diseases, Neurochem. Res., 29, 1979, 10.1007/s11064-004-6872-2 Plummer, 1946, Scrapie—a Disease of Sheep: a Review of the literature, Canadian Journal of Comparative Medicine and Veterinary Science, 10, 49 Srithayakumar, 2016, Identification of amino acid variation in the prion protein associated with classical scrapie in Canadian dairy goats, BMC Vet. Res., 12, 59, 10.1186/s12917-016-0684-x Liberski, 2015, Chapter 23 - Prion Diseases A2 - Zigmond, Michael J, 356 Belay, 2005, Variant Creutzfeldt-Jakob Disease Death, United States, Emerg. Infect. Dis., 11, 1351, 10.3201/eid1109.050371 Barnard, 2007, Direct Detection of Disease Associated Prions in Brain and Lymphoid Tissue using Antibodies Recognizing the Extreme N Terminus of PrP(C), Prion, 1, 121, 10.4161/pri.1.2.4439 Geschwind, 2015, Prion Diseases, Continuum (Minneapolis, Minn.), 21, 1612 T.J. Divers, Rebhun's Diseases of Dairy Cattle, 2nd Edition. Appleby, 2011, Rapidly progressive dementias and the treatment of human prion diseases, Expert. Opin. Pharmacother., 12, 1, 10.1517/14656566.2010.514903 Soto, 2011, Prion Hypothesis: the end of the Controversy?, Trends Biochem. Sci., 36, 151, 10.1016/j.tibs.2010.11.001 Tuite, 2010, The prion hypothesis: from biological anomaly to basic regulatory mechanism, Nat. Rev. Mol. Cell Biol., 11, 823, 10.1038/nrm3007 Harris, 1999, Cellular Biology of Prion Diseases, Clin. Microbiol. Rev., 12, 429, 10.1128/CMR.12.3.429 Lebrun, 2008, Susceptibility of cell substrates to PrP(Sc) infection and safety control measures related to biological and biotherapeutical products, Prion, 2, 17, 10.4161/pri.2.1.6280 Gajdusek, 1977, Unconventional viruses and the origin and disappearance of kuru, Science, 197, 943, 10.1126/science.142303 Hansel, 1999, Mad Cow Disease—the OR connection, AORN J., 70, 224, 10.1016/S0001-2092(06)62237-0 Prusiner, 1982, Novel proteinaceous infectious particles cause scrapie, Science, 216, 136, 10.1126/science.6801762 Chesebro, 1985, Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain, Nature, 315, 331, 10.1038/315331a0 Prusiner, 2001, Neurodegenerative Diseases and Prions, New England Journal of Medicine, 344, 1516, 10.1056/NEJM200105173442006 Aguzzi, 2008, Molecular mechanisms of prion pathogenesis, Annu. Rev. Pathol., 3, 11, 10.1146/annurev.pathmechdis.3.121806.154326 Colby, 2011, Prions, Cold Spring Harb. Perspect. Biol., 3, a006833, 10.1101/cshperspect.a006833 Miller, 2011, Superparamagnetic Nanoparticle Capture of Prions for Amplification, J. Virol., 85, 2813, 10.1128/JVI.02451-10 Safar, 2005, Diagnosis of human prion disease, Proc. Natl. Acad. Sci. U. S. A., 102, 3501, 10.1073/pnas.0409651102 Madec, 1998, Sensitivity of the Western blot detection of prion protein PrPres in natural sheep scrapie, J. Virol. Methods, 75, 169, 10.1016/S0166-0934(98)00113-X Saborio, 2001, Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding, Nature, 411, 810, 10.1038/35081095 Shan, 2016, Establishment of a simple cell-based ELISA for the direct detection of abnormal isoform of prion protein from prion-infected cells without cell lysis and proteinase K treatment, Prion, 10, 305, 10.1080/19336896.2016.1189053 Chen, 2010, Estimating prion concentration in fluids and tissues by quantitative PMCA, Nat. Methods, 7, 519, 10.1038/nmeth.1465 Giles, 2017, Developing Therapeutics for PrP Prion Diseases, Cold Spring Harb Perspect Med, 7, 10.1101/cshperspect.a023747 Walker, 2015, Neurodegenerative Diseases: Expanding the Prion Concept, Annu. Rev. Neurosci., 38, 87, 10.1146/annurev-neuro-071714-033828 Forloni, 2013, Therapy in prion diseases, Curr. Top. Med. Chem., 13, 2465, 10.2174/15680266113136660173 Panegyres, 2013, Therapies for human prion diseases, American Journal of Neurodegenerative Disease, 2, 176 Burchell, 2016, Prion diseases: immunotargets and therapy, ImmunoTargets and Therapy, 5, 57 Bevacqua, 2016, Efficient edition of the bovine PRNP prion gene in somatic cells and IVF embryos using the CRISPR/Cas9 system, Theriogenology, 86, 1886, 10.1016/j.theriogenology.2016.06.010 White, 2009, Therapy for prion diseases: Insights from the use of RNA interference, Prion, 3, 121, 10.4161/pri.3.3.9289 Ai Tran, 2010, A novel class of potential prion drugs: preliminary in vitro and in vivo data for multilayer coated gold nanoparticles, Nanoscale, 2, 2724, 10.1039/c0nr00551g Kouassi, 2006, A nanoparticle-based immobilization assay for prion-kinetics study, Journal of Nanobiotechnology, 4, 1, 10.1186/1477-3155-4-8 Zhang, 2012, Gold nanoparticles as a label-free probe for the detection of amyloidogenic protein, Talanta, 89, 401, 10.1016/j.talanta.2011.12.052 Kouassi, 2007, Aptamer-mediated magnetic and gold-coated magnetic nanoparticles as detection assay for prion protein assessment, Biotechnol. Prog., 23, 1239 Zhan, 2014, Stable silver nanoparticles–aptamer bioconjugates for cellular prion protein imaging, Chin. Sci. Bull., 59, 964, 10.1007/s11434-014-0122-z Zhang, 2014, An aptamer-functionalized gold nanoparticle biosensor for the detection of prion protein, Anal. Methods, 6, 2982, 10.1039/C3AY42207K Henry, 2004, Development of a nanoparticle-based surface-modified fluorescence assay for the detection of prion proteins, Anal. Biochem., 334, 1, 10.1016/j.ab.2004.07.008 Calvo, 2001, PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases, J. Neurosci. Methods, 111, 151, 10.1016/S0165-0270(01)00450-2 Bäumer, 2014, Advances in motor neurone disease, J. R. Soc. Med., 107, 14, 10.1177/0141076813511451 Van den Berg-Vos, 2003, The spectrum of lower motor neuronsyndromes, J. Neurol., 250, 1279, 10.1007/s00415-003-0235-9 Rezania, 2013, Spinal cord: motor neuron diseases, Neurol. Clin., 31, 219, 10.1016/j.ncl.2012.09.014 Moloney, 2014, ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease, Front. Neurosci., 8, 252, 10.3389/fnins.2014.00252 Zarei, 2015, A comprehensive review of amyotrophic lateral sclerosis, Surg. Neurol. Int., 6, 1, 10.4103/2152-7806.169561 Talbot, 2002, Motor neurone disease, Postgrad. Med. J., 78, 513, 10.1136/pmj.78.923.513 Wijesekera, 2009, Amyotrophic lateral sclerosis, Orphanet Journal of Rare Diseases, 4, 3, 10.1186/1750-1172-4-3 Kübler, 2005, Patients with ALS can use sensorimotor rhythms to operate a brain-computer interface, Neurology, 64, 1775, 10.1212/01.WNL.0000158616.43002.6D Zoccolella, 2009, Current and emerging treatments for amyotrophic lateral sclerosis, Neuropsychiatr. Dis. Treat., 5, 577, 10.2147/NDT.S7788 Tang, 2017, Amyotrophic lateral sclerosis disease modifying therapeutics: a cell biological perspective, Neural Regen. Res., 12, 407, 10.4103/1673-5374.202943 Couthouis, 2014, Targeted Exon Capture and Sequencing in sporadic Amyotrophic Lateral Sclerosis, PLoS Genet., 10, 10.1371/journal.pgen.1004704 Renton, 2013, State of play in amyotrophic lateral sclerosis genetics, Nat. Neurosci., 17, 17, 10.1038/nn.3584 Morgan, 2016, Pathogenesis of amyotrophic lateral sclerosis, Br. Med. Bull., 119, 87, 10.1093/bmb/ldw026 Kiernan, 2011, Amyotrophic lateral sclerosis, Lancet, 377, 942, 10.1016/S0140-6736(10)61156-7 Lall, 2017, Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia, J. Clin. Invest., 127, 3250, 10.1172/JCI90607 Tripolszki, 2017, Genetic analysis of the SOD1 and C9ORF72 genes in Hungarian patients with amyotrophic lateral sclerosis, Neurobiology of Aging, 53, 195.e191, 10.1016/j.neurobiolaging.2017.01.016 Chi, 2016, Distinct neurological disorders with C9orf72 mutations: genetics, pathogenesis, and therapy, Neurosci. Biobehav. Rev., 66, 127, 10.1016/j.neubiorev.2016.03.033 Andersen, 2011, Clinical genetics of amyotrophic lateral sclerosis: what do we really know?, Nat. Rev. Neurol., 7, 603, 10.1038/nrneurol.2011.150 Rosen, 1993, Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, Nature, 362, 59, 10.1038/362059a0 Prudencio, 2011, Superoxide dismutase 1 encoding mutations linked to ALS adopts a spectrum of misfolded states, Mol. Neurodegener., 6, 77, 10.1186/1750-1326-6-77 Bruijn, 1998, Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1, Science, 281, 1851, 10.1126/science.281.5384.1851 Pramatarova, 2001, Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment, J. Neurosci., 21, 3369, 10.1523/JNEUROSCI.21-10-03369.2001 Lino, 2002, Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease, J. Neurosci., 22, 4825, 10.1523/JNEUROSCI.22-12-04825.2002 Yamanaka, 2008, Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis, Nat. Neurosci., 11, 251, 10.1038/nn2047 Clement, 2003, Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS mice, Science, 302, 113, 10.1126/science.1086071 Xiao, 2007, Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia, J. Neurochem., 102, 2008, 10.1111/j.1471-4159.2007.04677.x Hall, 1998, Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS, Glia, 23, 249, 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-# Boillée, 2008, Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1, J. Clin. Invest., 118, 474 Pokrishevsky, 2012, Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis, PLoS One, 7, 10.1371/journal.pone.0035050 Ng, 2017, Intermediate C9orf72 alleles in neurological disorders: does size really matter?, J. Med. Genet., 54, 591, 10.1136/jmedgenet-2017-104752 DeJesus-Hernandez, 2011, Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS, Neuron, 72, 245, 10.1016/j.neuron.2011.09.011 Ciura, 2013, Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis, Ann. Neurol., 74, 180 Wojciechowska, 2011, Cellular toxicity of expanded RNA repeats: focus on RNA foci, Hum. Mol. Genet., 20, 3811, 10.1093/hmg/ddr299 Haeusler, 2014, C9orf72 nucleotide repeat structures initiate molecular cascades of disease, Nature, 507, 195, 10.1038/nature13124 Mackenzie, 2013, Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations, Acta Neuropathol., 126, 859, 10.1007/s00401-013-1181-y Jovičić, 2015, Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS, Nat. Neurosci., 18, 1226, 10.1038/nn.4085 Miller, 2012, Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), Cochrane Database Syst. Rev., 10.1002/14651858.CD001447.pub3 G. Amyotrophic Lateral Sclerosis/Riluzole Study, 1996, Dose-ranging study of riluzole in amyotrophic lateral sclerosis, The Lancet, 347, 1425, 10.1016/S0140-6736(96)91680-3 Takei, 2017, Edaravone and its clinical development for amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18, 5, 10.1080/21678421.2017.1353101 Scott, 2017, On the treatment trail for ALS, Nature, 550, S120, 10.1038/550S120a Ito, 2008, Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice, Exp. Neurol., 213, 448, 10.1016/j.expneurol.2008.07.017 Abe, 2014, Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15, 610, 10.3109/21678421.2014.959024 Hardiman, 2017, Edaravone: a new treatment for ALS on the horizon?, The Lancet Neurology, 16, 490, 10.1016/S1474-4422(17)30163-1 Mazibuko, 2015, A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders, J. Pharm. Sci., 104, 1213, 10.1002/jps.24322 Wagner, 2009, Biomarkers: Principles, Policies, and Practice, Clinical Pharmacology & Therapeutics, 86, 3, 10.1038/clpt.2009.77 Roney, 2005, Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer's disease, J. Control. Release, 108, 193, 10.1016/j.jconrel.2005.07.024 Jablonski, 2014, Inhibiting drug efflux transporters improves efficacy of ALS therapeutics, Annals of Clinical and Translational Neurology, 1, 996, 10.1002/acn3.141 Chen, 2017, Improving the Delivery of SOD1 Antisense Oligonucleotides to Motor Neurons Using Calcium Phosphate-Lipid Nanoparticles, Frontiers in Neuroscience, 11, 10.3389/fnins.2017.00476 Ross, 2011, Huntington's disease: from molecular pathogenesis to clinical treatment, The Lancet Neurology, 10, 83, 10.1016/S1474-4422(10)70245-3 Das, 2016, Huntingtin interacting protein HYPK is a negative regulator of heat shock response and is downregulated in models of Huntington's Disease, Exp. Cell Res., 343, 107, 10.1016/j.yexcr.2016.03.021 Kay, 2016, I2 Huntington's disease reduced penetrance alleles occur at high frequency and affect age-related increases in prevalence, Journal of Neurology, Neurosurgery &amp, Psychiatry, 87, A59 Lipe, 2009, Late Onset Huntington Disease: Clinical and Genetic Characteristics of 34 cases, J. Neurol. Sci., 276, 159, 10.1016/j.jns.2008.09.029 Chial, 2008, Huntington's Disease: the Discovery of the Huntingtin Gene, Nature Education, 1, 1 Shannon, 2011, Chapter 1 - Huntington's disease – clinical signs, symptoms, presymptomatic diagnosis, and diagnosis, 3, 10.1016/B978-0-444-52014-2.00001-X Rosenblatt, 1999 Warby, 2010 Rosenblatt, 2007, Neuropsychiatry of Huntington's disease, Dialogues Clin. Neurosci., 9, 191, 10.31887/DCNS.2007.9.2/arosenblatt Raj, 2015, Bipolar affective disorder in Huntington's disease: a neuropsychiatric perspective, Indian J. Psychiatry, 57, 107, 10.4103/0019-5545.148546 Paulsen, 2011, Cognitive Impairment in Huntington Disease: Diagnosis and Treatment, Current neurology and neuroscience reports, 11, 474, 10.1007/s11910-011-0215-x Stout, 2001, Risky decision making in Huntington's disease, J. Int. Neuropsychol. Soc., 7, 92, 10.1017/S1355617701711095 Budworth, 2013, 1010, 3 C.A. Ross, S.J. Tabrizi, Huntington's disease: from molecular pathogenesis to clinical treatment, The Lancet Neurology, 10 83–98. Schulte, 2011, The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology, Current trends in neurology, 5, 65 Menon, 2013, The Role of Interruptions in polyQ in the Pathology of SCA1, PLoS Genet., 9, 10.1371/journal.pgen.1003648 Kim, 2014, Pathogenic polyglutamine expansion length correlates with polarity of the flanking sequences, Mol. Neurodegener., 9, 45, 10.1186/1750-1326-9-45 Hendricks, 2009, Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27–35 CAG), Am. J. Med. Genet. A, 149A, 1375, 10.1002/ajmg.a.32901 Wexler, 2012, Huntington's Disease: Advocacy Driving Science, Annu. Rev. Med., 63, 1, 10.1146/annurev-med-050710-134457 Pearson, 2003, Slipping while sleeping? Trinucleotide repeat expansions in germ cells, Trends Mol. Med., 9, 490, 10.1016/j.molmed.2003.09.006 Bathina, 2015, Brain-derived neurotrophic factor and its clinical implications, Archives of Medical Science : AMS, 11, 1164, 10.5114/aoms.2015.56342 Zuccato, 2007, Role of brain-derived neurotrophic factor in Huntington's disease, Prog. Neurobiol., 81, 294, 10.1016/j.pneurobio.2007.01.003 Cisbani, 2012, An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity, Cell Death Dis., 3, 10.1038/cddis.2012.121 Juenemann, 2013, Expanded Polyglutamine-containing N-terminal Huntingtin Fragments are Entirely Degraded by Mammalian Proteasomes, J. Biol. Chem., 288, 27068, 10.1074/jbc.M113.486076 Arndt, 2015, The emerging role of the first 17 amino acids of huntingtin in Huntington's disease, Biomolecular concepts, 6, 33, 10.1515/bmc-2015-0001 Chen, 2017, Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease, Proc. Natl. Acad. Sci. U. S. A., 114, 4406, 10.1073/pnas.1702237114 Schilling, 2007, Characterization of Huntingtin Pathologic Fragments in Human Huntington Disease, Transgenic Mice, and Cell Models, Journal of Neuropathology & Experimental Neurology, 66, 313, 10.1097/nen.0b013e318040b2c8 Sari, 2011, Huntington's Disease: from Mutant Huntingtin Protein to Neurotrophic factor Therapy, International Journal of Biomedical Science : IJBS, 7, 89 Saleh, 2014, Cytotoxicity of Mutant Huntingtin Fragment in yeast can be Modulated by the Expression Level of Wild Type Huntingtin Fragment, ACS Chem. Neurosci., 5, 205, 10.1021/cn400171d Bhide, 1996, Expression of Normal and Mutant Huntingtin in the developing Brain, J. Neurosci., 16, 5523, 10.1523/JNEUROSCI.16-17-05523.1996 Frank, 2014, Treatment of Huntington's Disease, Neurotherapeutics, 11, 153, 10.1007/s13311-013-0244-z Videnovic, 2013, Treatment of Huntington Disease, Curr. Treat. Options Neurol., 15, 424, 10.1007/s11940-013-0219-8 Valenza, 2015, Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice, EMBO Molecular Medicine, 7, 1547, 10.15252/emmm.201505413 Debnath, 2017, Poly(trehalose) Nanoparticles prevent Amyloid Aggregation and Suppress Polyglutamine Aggregation in a Huntington's Disease Model Mouse, ACS Appl. Mater. Interfaces, 9, 24126, 10.1021/acsami.7b06510 Sandhir, 2014, Curcumin Nanoparticles Attenuate Neurochemical and Neurobehavioral Deficits in Experimental Model of Huntington's Disease, NeuroMolecular Med., 16, 106, 10.1007/s12017-013-8261-y Ramachandran, 2016, A novel therapeutic application of solid lipid nanoparticles encapsulated thymoquinone (TQ-SLNs) on 3-nitroproponic acid induced Huntington's disease-like symptoms in wistar rats, Chem. Biol. Interact., 256, 25, 10.1016/j.cbi.2016.05.020 Godinho, 2015, Delivering a disease-modifying treatment for Huntington's disease, Drug Discov. Today, 20, 50, 10.1016/j.drudis.2014.09.011 Abhishek, 2014, Prospects for neuroprotective therapies in prodromal Huntington's disease, Mov. Disord., 29, 285, 10.1002/mds.25835 Pradhan, 2018, Inhibition of Protein Aggregation by Iron Oxide Nanoparticles Conjugated with Glutamine- and Proline-based Osmolytes, ACS Applied Nano Materials, 1, 1094, 10.1021/acsanm.7b00245 Bhatt, 2015, Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease, Drug Delivery, 22, 931, 10.3109/10717544.2014.880860 Godinho, 2013, Self-assembling Modified β-Cyclodextrin Nanoparticles as Neuronal siRNA delivery Vectors: Focus on Huntington's Disease, Mol. Pharm., 10, 640, 10.1021/mp3003946 Puneet Opal, 1993 Rossi, 2014, Autosomal dominant cerebellar ataxias: a systematic review of clinical features, Eur. J. Neurol., 21, 607, 10.1111/ene.12350 Choubtum, 2015, Analysis of SCA8, SCA10, SCA12, SCA17 and SCA19 in patients with unknown spinocerebellar ataxia: a Thai multicentre study, BMC Neurol., 15, 166, 10.1186/s12883-015-0425-y Rosenberg, 2015, 811 Dohlinger, 2008, Magnetic resonance imaging in spinocerebellar ataxias, Cerebellum, 7, 204, 10.1007/s12311-008-0025-0 Öz, 2010, Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status, Movement disorders : Journal of the Movement Disorder Society, 25, 1253, 10.1002/mds.23067 Alves, 2008, Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease, Hum. Mol. Genet., 17, 2071, 10.1093/hmg/ddn106 Scoles, 2017, Antisense oligonucleotide therapy for spinocerebellar ataxia type 2, Nature, 544, 362, 10.1038/nature22044 Harini, 2014, Treatment Options in Degenerative Cerebellar Ataxia: a Systematic Review, Movement Disorders Clinical Practice, 1, 291, 10.1002/mdc3.12057 Malhotra, 2013, Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases, Biomaterials, 34, 1270, 10.1016/j.biomaterials.2012.10.013 Shiba, 2007, Potential Usefulness of the D2R Reporter Gene Imaging by IBF as a Gene Therapy Monitoring for Cerebellar Disorder, Journal of Nuclear Medicine, 48, 242 Bonanomi, 2014, Epigallocatechin-3-gallate and tetracycline differently affect ataxin-3 fibrillogenesis and reduce toxicity in spinocerebellar ataxia type 3 model, Hum. Mol. Genet., 23, 6542, 10.1093/hmg/ddu373 Wang, 2018, Experimental and Clinical strategies for Treating Spinocerebellar Ataxia Type 3, Neuroscience, 371, 138, 10.1016/j.neuroscience.2017.11.051 Crawford, 1996, The Neurobiology of Childhood Spinal Muscular Atrophy, Neurobiol. Dis., 3, 97, 10.1006/nbdi.1996.0010 D'Amico, 2011, Spinal muscular atrophy, Orphanet Journal of Rare Diseases, 6, 1, 10.1186/1750-1172-6-71 Ogino, 2002, Genetic risk assessment in carrier testing for spinal muscular atrophy, Am. J. Med. Genet., 110, 301, 10.1002/ajmg.10425 Lefebvre, 1995, Identification and characterization of a spinal muscular atrophy-determining gene, Cell, 80, 155, 10.1016/0092-8674(95)90460-3 Pellizzoni, 2007, Chaperoning ribonucleoprotein biogenesis in health and disease, EMBO Rep., 8, 340, 10.1038/sj.embor.7400941 Burghes, 2009, Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?, Nat. Rev. Neurosci., 10, 597, 10.1038/nrn2670 Monani, 2005, Spinal Muscular Atrophy: a Deficiency in a Ubiquitous Protein; a Motor Neuron-specific Disease, Neuron, 48, 885, 10.1016/j.neuron.2005.12.001 Burnett, 2009, Emerging treatment options for spinal muscular atrophy, Curr. Treat. Options Neurol., 11, 90, 10.1007/s11940-009-0012-x Schmid, 2007, Animal Models of Spinal Muscular Atrophy, J. Child Neurol., 22, 1004, 10.1177/0883073807305667 Arnold, 2015, Spinal Muscular Atrophy: Diagnosis and Management in a New Therapeutic Era, Muscle Nerve, 51, 157, 10.1002/mus.24497 Baioni, 2010, Atrofia muscular espinhal: diagnóstico, tratamento e perspectivas futuras, J. Pediatr., 86, 261 Chiriboga, 2017, Nusinersen for the treatment of spinal muscular atrophy, Expert. Rev. Neurother., 17, 955, 10.1080/14737175.2017.1364159 Shi, 2014, The lack of CuZnSOD leads to Impaired Neurotransmitter Release, Neuromuscular Junction Destabilization and Reduced Muscle Strength in mice, PLoS One, 9 Shabanpoor, 2017, Identification of a Peptide for Systemic Brain delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy, Nucleic Acid Therapeutics, 27, 130, 10.1089/nat.2016.0652 Singh, 2008, DcpS as a Therapeutic Target for Spinal Muscular Atrophy, ACS Chem. Biol., 3, 711, 10.1021/cb800120t Fangerau, 2004, Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria, Acta Neurol. Scand., 109, 385, 10.1111/j.1600-0404.2004.00246.x Ellidag, 2013, Comparison of neurophysiological and MRI findings of patients with multiple sclerosis using oligoclonal band technique, Ann. Neurosci., 20, 149, 10.5214/ans.0972.7531.200406 McDonald, 2001, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann. Neurol., 50, 121, 10.1002/ana.1032 Ahmadpour-Yazdi, 2015, Colourimetric-based method for the diagnosis of spinal muscular atrophy using gold nanoprobes, IET Nanobiotechnol, 9, 5, 10.1049/iet-nbt.2013.0065 Compston, 2008, Multiple sclerosis, Lancet, 372, 1502, 10.1016/S0140-6736(08)61620-7 Weinshenker, 1996, Epidemiology of multiple sclerosis, Neurol. Clin., 14, 291, 10.1016/S0733-8619(05)70257-7 Hauser, 2012, Chapter 380. Multiple Sclerosis and Other Demyelinating Diseases Koch-Henriksen, 2010, The changing demographic pattern of multiple sclerosis epidemiology, The Lancet Neurology, 9, 520, 10.1016/S1474-4422(10)70064-8 Loma, 2011, Multiple Sclerosis: Pathogenesis and Treatment, Curr. Neuropharmacol., 9, 409, 10.2174/157015911796557911 Miller, 2012, Clinically isolated syndromes, The Lancet Neurology, 11, 157, 10.1016/S1474-4422(11)70274-5 Stephens, 2003, A Comparison of Bayesian Methods for Haplotype Reconstruction from Population Genotype Data, Am. J. Hum. Genet., 73, 1162, 10.1086/379378 Ascherio, 2007, Environmental risk factors for multiple sclerosis. Part I: the role of infection, Ann. Neurol., 61, 288, 10.1002/ana.21117 Singh, 2009, Anomalous venous blood flow and iron deposition in multiple sclerosis, J. Cereb. Blood Flow Metab., 29, 1867, 10.1038/jcbfm.2009.180 Frischer, 2009, The relation between inflammation and neurodegeneration in multiple sclerosis brains, Brain, 132, 1175, 10.1093/brain/awp070 Katzberg, 2010, Assessment: Symptomatic treatment for muscle cramps (an evidence-based review), Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, 74, 691 Frohman, 2006, Multiple Sclerosis — the Plaque and its Pathogenesis, N. Engl. J. Med., 354, 942, 10.1056/NEJMra052130 Wuest, 2011, A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy, Nat. Med., 17, 604, 10.1038/nm.2365 Kaur, 2013, Natural killer cells and their receptors in multiple sclerosis, Brain, 136, 2657, 10.1093/brain/aws159 Bielekova, 2000, Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand, Nat. Med., 6, 1167, 10.1038/80516 Tsang, 2011, Multiple sclerosis- diagnosis, management and prognosis, Aust. Fam. Physician, 40, 948 Xu, 2015, Dimethyl fumarate for multiple sclerosis, Cochrane Database Syst. Rev., 10.1002/14651858.CD011076.pub2 Karaborni, 2015 Santamaria, 2016 Liu, 2017, Oxidative stress in Neurodegenerative Diseases: from Molecular Mechanisms to Clinical applications, Oxidative Med. Cell. Longev., 2017, 2525967, 10.1155/2017/2525967 Shoulson, 1998, Where do we stand on neuroprotection? Where do we go from here?, Mov. Disord., 13, 46 Albarracin, 2012, Effects of natural antioxidants in neurodegenerative disease, Nutr. Neurosci., 15, 1, 10.1179/1476830511Y.0000000028 Rao, 2002, Role of oxidative stress and antioxidants in neurodegenerative diseases, Nutr. Neurosci., 5, 291, 10.1080/1028415021000033767 Levi, 2004, A review of neuroprotective agents, Curr. Med. Chem., 11, 2383, 10.2174/0929867043364522 Bavarsad Shahripour, 2014, N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities, Brain and Behavior, 4, 108, 10.1002/brb3.208 Spector, 2007, REVIEW: Vitamin transport and homeostasis in mammalian brain: focus on Vitamins B and E, J. Neurochem., 103, 425, 10.1111/j.1471-4159.2007.04773.x Agus, 1997, Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters, J. Clin. Invest., 100, 2842, 10.1172/JCI119832 Merav, 2005, A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease, Eur. J. Neurosci., 21, 637, 10.1111/j.1460-9568.2005.03889.x Caputo, 2017, A novel synthetic approach of cerium oxide nanoparticles with improved biomedical activity, Sci. Rep., 7, 4636, 10.1038/s41598-017-04098-6 Das, 2007, Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons, Biomaterials, 28, 1918, 10.1016/j.biomaterials.2006.11.036 Singh, 2016, Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG), Nutr. J., 15, 60, 10.1186/s12937-016-0179-4 Xu, 2016, Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: a potential Agent for Parkinson's Disease, Neurochem. Res., 41, 2788, 10.1007/s11064-016-1995-9 Weinreb, 2009, Neuroprotective molecular mechanisms of (−)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties, Genes Nutr., 4, 283, 10.1007/s12263-009-0143-4 Mähler, 2013, Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?, EPMA J., 4, 1, 10.1186/1878-5085-4-5 Rezai-Zadeh, 2008, Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice, Brain Res., 1214, 177, 10.1016/j.brainres.2008.02.107 Cascella, 2017, The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer's disease: an overview of pre-clinical studies and translational perspectives in clinical practice, Infectious Agents and Cancer, 12, 36, 10.1186/s13027-017-0145-6 Nelson, 2009, Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity, FEBS Lett., 583, 3569, 10.1016/j.febslet.2009.10.062 Ehrnhoefer, 2006, Green tea (−)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models, Hum. Mol. Genet., 15, 2743, 10.1093/hmg/ddl210 Bieschke, 2010, EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity, Proc. Natl. Acad. Sci., 107, 7710, 10.1073/pnas.0910723107 Smith, 2010, Nanolipidic particles improve the bioavailability and α-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease, Int. J. Pharm., 389, 207, 10.1016/j.ijpharm.2010.01.012 Siddiqui, 2010, Nanochemoprevention by Bioactive Food Components: a Perspective, Pharm. Res., 27, 1054, 10.1007/s11095-010-0087-9 Godoi, 2013, Selenium Compounds prevent Amyloid β-Peptide Neurotoxicity in Rat primary Hippocampal Neurons, Neurochem. Res., 38, 2359, 10.1007/s11064-013-1147-4 Bellinger, 2009, Regulation and function of selenoproteins in human disease, The Biochemical journal, 422, 11, 10.1042/BJ20090219 Zhang, 2014, Epigallocatechin-3-gallate (EGCG)-Stabilized Selenium Nanoparticles Coated with Tet-1 Peptide to Reduce Amyloid-β Aggregation and Cytotoxicity, ACS Appl. Mater. Interfaces, 6, 8475, 10.1021/am501341u Esteves, 2015, Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease, Front. Aging Neurosci., 7, 20, 10.3389/fnagi.2015.00020 Wu, 2013, Neurotoxic potential of iron oxide nanoparticles in the rat brain striatum and hippocampus, Neurotoxicology, 34, 243, 10.1016/j.neuro.2012.09.006 Han, 2011, Nano-zinc oxide damages spatial cognition capability via over-enhanced long-term potentiation in hippocampus of Wistar rats, Int. J. Nanomedicine, 6, 1453 Chen, 2011, Effects of titanium dioxide nano-particles on growth and some histological parameters of zebrafish (Danio rerio) after a long-term exposure, Aquat. Toxicol., 101, 493, 10.1016/j.aquatox.2010.12.004 Gref, 2000, ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption, Colloids Surf. B: Biointerfaces, 18, 301, 10.1016/S0927-7765(99)00156-3 Chang, 2009, Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood–brain barrier, Int. J. Pharm., 379, 285, 10.1016/j.ijpharm.2009.04.035 Oyewumi, 2003, Specific Association of Thiamine-Coated Gadolinium Nanoparticles with Human Breast Cancer Cells Expressing Thiamine Transporters, Bioconjug. Chem., 14, 404, 10.1021/bc0340013 Grover, 2014, Brain-Targeted delivery of Docetaxel by Glutathione-Coated Nanoparticles for Brain Cancer, AAPS PharmSciTech, 15, 1562, 10.1208/s12249-014-0165-0 Fabbro, 2011, Chapter 18 - Interfacing neurons with carbon nanotubes:: (re)engineering neuronal signaling, 241, 10.1016/B978-0-444-53815-4.00003-0 Ekinci, 2010, High-frequency nanofluidics: a universal formulation of the fluid dynamics of MEMS and NEMS, Lab Chip, 10, 3013, 10.1039/c003770m Wang, 2014, Multifunctional 1D magnetic and Fluorescent Nanoparticle chains for Enhanced MRI, fluorescent Cell Imaging, And Combined Photothermal/Chemotherapy, ACS Applied Materials & Interfaces, 6, 15309, 10.1021/am503777k Carvalho, 2014, Enhanced contrast efficiency in MRI by PEGylated magnetoliposomes loaded with PEGylated SPION: effect of SPION coating and micro-environment, Mater. Sci. Eng. C, 43, 521, 10.1016/j.msec.2014.07.055 Medina, 2007, Nanoparticles: pharmacological and toxicological significance, Br. J. Pharmacol., 150, 552, 10.1038/sj.bjp.0707130 Repar, 2018, Silver nanoparticles induce neurotoxicity in a human embryonic stem cell-derived neuron and astrocyte network, Nanotoxicology, 12, 104, 10.1080/17435390.2018.1425497 Mirsattari, 2004, Myoclonic status epilepticus following repeated oral ingestion of colloidal silver, Neurology, 62, 1408, 10.1212/01.WNL.0000120671.73335.EC Shimizu, 2009, Maternal exposure to nanoparticulate titanium dioxide during the prenatal period alters gene expression related to brain development in the mouse, Particle and Fibre Toxicology, 6, 20, 10.1186/1743-8977-6-20 Mohammadipour, 2014, Maternal exposure to titanium dioxide nanoparticles during pregnancy; impaired memory and decreased hippocampal cell proliferation in rat offspring, Environ. Toxicol. Pharmacol., 37, 617, 10.1016/j.etap.2014.01.014 Wilhelmi, 2013, Zinc Oxide Nanoparticles Induce Necrosis and Apoptosis in Macrophages in a p47phox- and Nrf2-Independent Manner, PLoS One, 8, 10.1371/journal.pone.0065704 Weissleder, 2014, Imaging macrophages with nanoparticles, Nat. Mater., 13, 125, 10.1038/nmat3780 Patel, 2015, Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases, Theranostics, 5, 150, 10.7150/thno.9476 Chouly, 1996, Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution, J. Microencapsul., 13, 245, 10.3109/02652049609026013 Shebl, 2017, Effect of Surface Charge and Hydrophobicity Modulation on the Antibacterial and Antibiofilm potential of magnetic Iron Nanoparticles, J. Nanomater., 2017, 15, 10.1155/2017/3528295 Mohammed, 2017, Magnetic nanoparticles for environmental and biomedical applications: a review, Particuology, 30, 1, 10.1016/j.partic.2016.06.001 Doshi, 2010, Macrophages recognize size and shape of their targets, PLoS One, 5, 10.1371/journal.pone.0010051 Nowacek, 2011, Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages, J. Control. Release, 150, 204, 10.1016/j.jconrel.2010.11.019 MacParland, 2017, Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood, ACS Nano, 11, 2428, 10.1021/acsnano.6b06245 Batrakova, 2011, Cell-mediated drug delivery, Expert Opin Drug Deliv, 8, 415, 10.1517/17425247.2011.559457 Batrakova, 2010, Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers, J. Control. Release, 143, 290, 10.1016/j.jconrel.2010.01.004 McMillan, 2011, Cell delivery of therapeutic nanoparticles, Prog. Mol. Biol. Transl. Sci., 104, 563, 10.1016/B978-0-12-416020-0.00014-0 McMillan, 2011, Chapter 14 - Cell Delivery of Therapeutic Nanoparticles, 563, 10.1016/B978-0-12-416020-0.00014-0 Singh, 2014, Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues, Nanomedicine, 9, 469, 10.2217/nnm.14.4 Singh, 2014, Gendelman, Bench-to-bedside translation of magnetic nanoparticles, Nanomedicine, 9, 501, 10.2217/nnm.14.5 L.K. Ferreira, J.M. Rondina, R. Kubo, C.R. Ono, C.C. Leite, J. Smid, C. Bottino, R. Nitrini, G.F. Busatto, F.L. Duran, C.A. Buchpiguel, Support vector machine-based classification of neuroimages in Alzheimer's disease: direct comparison of FDG-PET, rCBF-SPECT and MRI data acquired from the same individuals, Rev. Bras. Psiquiatr., (2017) 0. Vasquez, 2011, Quantitative whole Body Biodistribution of Fluorescent-Labeled Agents by Non-Invasive Tomographic Imaging, PLoS One, 6, 10.1371/journal.pone.0020594 Bruckman, 2014, Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice, Virology, 449, 163, 10.1016/j.virol.2013.10.035 von Roemeling, 2017, Breaking down the Barriers to Precision Cancer Nanomedicine, Trends Biotechnol., 35, 159, 10.1016/j.tibtech.2016.07.006 Wolfbeis, 2015, An overview of nanoparticles commonly used in fluorescent bioimaging, Chem. Soc. Rev., 44, 4743, 10.1039/C4CS00392F Angelakeris, 2017, Magnetic nanoparticles: a multifunctional vehicle for modern theranostics, Biochim. Biophys. Acta Gen. Subj., 1861, 1642, 10.1016/j.bbagen.2017.02.022 Estelrich, 2015, Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents, Int. J. Nanomedicine, 10, 1727 Chen, 2014, Upconversion Nanoparticles: Design, Nanochemistry, and applications in Theranostics, Chem. Rev., 114, 5161, 10.1021/cr400425h Fuhrmann, 2014, Targeting of Injectable Drug Nanocrystals, Mol. Pharm., 11, 1762, 10.1021/mp5001247 Valencia, 2010, Single-step Assembly of Homogenous Lipid−Polymeric and Lipid−Quantum Dot Nanoparticles Enabled by Microfluidic Rapid Mixing, ACS Nano, 4, 1671, 10.1021/nn901433u Shen, 2017, Iron Oxide Nanoparticle based Contrast Agents for magnetic Resonance Imaging, Mol. Pharm., 14, 1352, 10.1021/acs.molpharmaceut.6b00839 Gupta, 2005, Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications, Biomaterials, 26, 3995, 10.1016/j.biomaterials.2004.10.012 Kattel, 2012, Paramagnetic dysprosium oxide nanoparticles and dysprosium hydroxide nanorods as T2 MRI contrast agents, Biomaterials, 33, 3254, 10.1016/j.biomaterials.2012.01.008 Li, 2018, One-pot preparation of hydrophilic manganese oxide nanoparticles as T1 nano-contrast agent for molecular magnetic resonance imaging of renal carcinoma in vitro and in vivo, Biosens. Bioelectron., 102, 1, 10.1016/j.bios.2017.10.047 Mimun, 2013, Bimodal Imaging using Neodymium Doped Gadolinium Fluoride Nanocrystals with Near-infrared to Near-infrared Downconversion Luminescence and magnetic Resonance Properties, J Mater Chem B Mater Biol Med, 1, 5702, 10.1039/c3tb20905a Reddy, 2012, Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications, Chem. Rev., 112, 5818, 10.1021/cr300068p Kuhn, 2014, Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages, Beilstein Journal of Nanotechnology, 5, 1625, 10.3762/bjnano.5.174 Gorantla, 2006, Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery, J. Leukoc. Biol., 80, 1165, 10.1189/jlb.0206110 Gorantla, 2012, Rodent models for HIV-associated neurocognitive disorders, Trends Neurosci., 35, 197, 10.1016/j.tins.2011.12.006 Eggleston, 2014, Molecular imaging of bacterial infections in vivo: the discrimination of infection from inflammation, Informatics (MDPI), 1, 72, 10.3390/informatics1010072 Petry, 2007, Magnetic resonance imaging of human brain macrophage infiltration, Neurotherapeutics, 4, 434, 10.1016/j.nurt.2007.05.005 Brochet, 2008, MRI to predict severe tissue damage in inflammatory lesions in animal models of multiple sclerosis, Brain, 131, e92, 10.1093/brain/awm261 Serkova, 2017, Nanoparticle-based magnetic Resonance Imaging on Tumor-Associated Macrophages and Inflammation, Front. Immunol., 8, 590, 10.3389/fimmu.2017.00590 Daldrup-Link, 2011, MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles, Clin. Cancer Res., 17, 5695, 10.1158/1078-0432.CCR-10-3420 Nahrendorf, 2008, Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis, Circulation, 117, 379, 10.1161/CIRCULATIONAHA.107.741181 Kratz, 2016, Atherosclerosis and Nanotechnology: Diagnostic and Therapeutic applications, Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, 30, 33, 10.1007/s10557-016-6649-2 Al Faraj, 2013, Preferential magnetic nanoparticle uptake by bone marrow derived macrophages sub-populations: effect of surface coating on polarization, toxicity, and in vivo MRI detection, J. Nanopart. Res., 15, 1797, 10.1007/s11051-013-1797-9 Raynal, 2004, Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10, Investig. Radiol., 39, 56, 10.1097/01.rli.0000101027.57021.28 Morishige, 2010, High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis, Circulation, 122, 1707, 10.1161/CIRCULATIONAHA.109.891804 Lipinski, 2009, Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis, JACC Cardiovasc. Imaging, 2, 637, 10.1016/j.jcmg.2008.08.009 Bagalkot, 2015, Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals, J. Control. Release, 217, 243, 10.1016/j.jconrel.2015.09.027 Wiart, 2007, Magnetic resonance imaging (MRI) of inflammation in stroke, Conf Proc IEEE Eng Med Biol Soc, 2007, 4316 Al Faraj, 2014, Preferential macrophage recruitment and polarization in LPS-induced animal model for COPD: noninvasive tracking using MRI, PLoS One, 9, 10.1371/journal.pone.0090829 Dousset, 1999, In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance, Magn. Reson. Med., 41, 329, 10.1002/(SICI)1522-2594(199902)41:2<329::AID-MRM17>3.0.CO;2-Z Keliher, 2017, Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease, Nat. Commun., 8, 14064, 10.1038/ncomms14064 Foss, 2017, Imaging Macrophage Accumulation in a Murine Model of Chronic Pancreatitis with (125)I-Iodo-DPA-713 SPECT/CT, J. Nucl. Med., 58, 1685, 10.2967/jnumed.117.189571 Van De Wiele, 2014, Targeting monocytes and macrophages by means of SPECT and PET, The quarterly journal of nuclear medicine and molecular imaging, 58, 269 Pérez-Medina, 2015, PET Imaging of Tumor-Associated Macrophages with (89)Zr-Labeled High-Density Lipoprotein Nanoparticles, J. Nucl. Med., 56, 1272, 10.2967/jnumed.115.158956 Baek, 2011, Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells, J. Neuro-Oncol., 104, 439, 10.1007/s11060-010-0511-3 Stockhofe, 2014, Radiolabeling of Nanoparticles and Polymers for PET Imaging, Pharmaceuticals, 7, 392, 10.3390/ph7040392 Locatelli, 2012, Biocompatible nanocomposite for PET/MRI hybrid imaging, Int. J. Nanomedicine, 7, 6021 Singh, 2013, Long term outcome of surgical treatment of fractures of pelvis, Journal of Oral and Maxillofacial Radiology, 1, 37, 10.4103/2321-3841.120094 Luehmann, 2014, PET/CT Imaging of Chemokine Receptor CCR5 in Vascular Injury Model using Targeted Nanoparticle, J. Nucl. Med., 55, 629, 10.2967/jnumed.113.132001 Farwell, 2014, PET/CT imaging in cancer: current applications and future directions, Cancer, 120, 3433, 10.1002/cncr.28860 Cheng, 2015, Detection of Vulnerable Atherosclerosis Plaques with a Dual-Modal Single-Photon-Emission Computed Tomography/magnetic Resonance Imaging Probe Targeting Apoptotic Macrophages, ACS Appl. Mater. Interfaces, 7, 2847, 10.1021/am508118x Cheng, 2014, Comparing 18F-FDG PET and 99mTc-labeled ultrasmall superparamagnetic iron oxide-conjugated annexin V SPECT/CT/MR imaging apoptosis in atherosclerotic plaques, J. Nucl. Med., 55, 1705 Venneti, 2004, PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS, J. Clin. Invest., 113, 981, 10.1172/JCI200420227